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ABSTRACT

COUP-TFII AND ITS INTERACTING PROTEINS IN BREAST CANCER AND
ENDOCRINE RESISTANCE
Lacey M. Litchfield
April 5, 2013
Chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) is an
orphan nuclear receptor that functions as either a transcriptional activator or repressor.
COUP-TFII expression is reduced in endocrine-resistant breast cancer cells and
overexpression of COUP-TFII restores the ability of antiestrogens to inhibit cell
proliferation. In this study, I tested the hypothesis that the activity of COUP-TFII in
maintenance of endocrine sensitivity and cell differentiation is dependent on its
interacting proteins. A direct interaction was identified between COUP-TFII and the
phosphoprotein nucleolin, which was found to flIDction as a coregulator for COUP-TFIImediated transcription. COUP-TFII increased the expression of the tumor suppressor
retinoic acid receptor B2 (RARB2) in a nucleolin-dependent manner. COUP-TFII and
nucleolin expression were correlated in estrogen receptor a (ERa)+ invasive ductal
carcinomas. COUP-TFII expression was inversely correlated with patient tumor grade.
Aberrant activation of the NFKB pathway has also been implicated in endocrine
resistance.

COUP-TFII trans feet ion suppressed NFKB activity in endocrine-resistant

breast cancer cells. COUP-TFII overexpression also reduced the expression of NFKB

IV

target genes (IL6, ICAMl, TNFAIP3, and CCL2) and subunits (NFKBl, REL, RELA, and

RELB) through a mechanism involving interaction of COUP- TFII with NFK13 subunits
RelB and NFK131 to inhibit NFK13 DNA-binding. COUP-TFII also reduced the ability of
coactivators SRC-l, SRC-3, and CBP to enhance NFK13 activity. An inverse correlation
between COUP-TFII and IL6, ICAMl, TNFAIP3, NFKB2, REL, RELA, and RELB was
observed in breast tumors from tamoxifen-treated breast cancer patients.

The

combination of COUP-TFII overexpression, NFK13 inhibition, and tamoxifen treatment
inhibited the growth of endocrine-resistant breast cancer cells. Endocrine-resistant breast
cancer cells were more sensitive to treatment with an NFK13 inhibitor than endocrinesensitive cells, reflecting their reliance on the NFK13 pathway for survival.
To further explore the role of COUP-TFII-interacting proteins

III

endocrine

sensitivity, mass spectrometry was used to identify proteins that interacted with COUP-

TFII specifically when breast cancer cells were treated with tamoxifen versus vehicle
control. HSP27 was selected for follow-up from the proteins identified as interacting
specifically with COUP-TFII in cells treated with tamoxifen. HSP27 expression was
reduced in an endocrine-resistant breast cancer cell line that has undergone epithelial to
mesenchymal transition, LY2, as well as in a trastuzumab-resistant breast cancer cell line,
JIMT -1. A concomitant reduction in COUP-TFII expression was also observed in these
cells. Future studies will explore the role of COUP-TFII-HSP27 interaction in resistance
to tamoxifen and trastuzumab. COUP-TFII may be both a useful biomarker to predict
tamoxifen and/or trastuzurnab sensitivity as well as a target to restore sensitivity to
resistant cells.
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CHAPTER I - BREAST CANCER AND ENDOCRINE RESISTANCE

BREAST STRUCTURE AND DEVELOPMENT
The complex branched stmcture of the adult mammary gland is composed of two
basic cellular compartments: luminal and basal cells. Luminal epithelial cells line the
lumen of the mammary duct, while the basal compartment is composed of progenitor
cells and contractile myoepithelial cells that do not directly contact the ductal lumen.
Coordinated paracrine signaling as well as stmctural connections between these two
compartments are necessary for both the proper development and function of the
mammary gland [1].
In the late 1950s, endocrine ablation experiments in rats and mice demonstrated

that sequential timing of treatment with

1 7-~-estradiol

(E2), progesterone, and prolactin,

in the presence of cortisol and growth hormone, were the minimal hormones necessary
for mammary gland development [1].

Sequential hormone excretion and/or hormone

receptor expression is required for the formation of proper glandular stmcture. Estrogens
mediate the beginning of ductal branching and elongation as well as initial side
branching, followed by progesterone regulation of continued side branching and alveoli
formation.

Alveologenesis is completed by prolactin, which also regulates milk

production during the late stages of pregnancy [1] . Milk is produced in the lobules and
transported through the ductal system. The ducts and ductal-lobular units are extended
during puberty and further expand during pregnancy and lactation [2].
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Aberrant

proliferation can occur in both the duct and lobule structures to form ductal carcinoma or
lobular carcinoma, respectively, although ductal carcinomas are more common, i.e., 75%
of invasive breast cancers are ductal in origin, while 11 % are lobular (the remaining 14%
comprise a heterogeneous set of less common classifications) [3].

BREAST CANCER SUBTYPES
Breast cancer is the most commonly diagnosed cancer in women, and the leading
cause of cancer death in females aged 20-59 years [4]. Breast cancers can be divided into
5 basic SUbtypes based on their distinct gene expression data: normal breast-like, luminal
A, luminal B, ERBB2+, and basal [5-7]. The luminal A and luminal B groups express a
gene signature similar to that of the luminal epithelial cells of normal mammary tissue,
while the basal subtype is more reminiscent of basal epithelial cells [6,7]. Luminal B is
distinguished from luminal A by higher expression of the cell proliferation marker Ki67,
a biomarker associated with recurrence, relapse, and overall worse outcome in breast
cancer patients [8-11].

The ERBB2+ group is defined by overexpression of the

HER2/neu (ERBB2) receptor, a member of the epidermal growth factor receptor (EGFR)

family that is ligand-independent and constitutively active, a known oncogenic
transformation associated with poor outcome in breast cancer patients [12].

Normal

breast-like cancers express a gene signature similar to that of adipose tissue, basal
epithelial cells, and other nonepithelial components of the breast [5,7]. Breast cancer
SUbtype is also indicative of clinical outcome, with basal and ERBB2+ subtypes
associated with a statistically significant decrease in survival [5,6]. Luminal A tumors
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show the highest estrogen receptor a (ERa) expression of the five subtypes, while ERacancers generally fall in the ERBB2+ or basal subtypes [6,7].
ESTROGEN RECEPTOR FUNCTION

Estrogen' s action as the ovarian hormone responsible for maintenance of estrus
was first characterized in 1923 by Allen and Doisy using partially purified hormone from
the hog ovary [13].

Further investigation revealed three forms of estrogen: estrone,

estriol, and estradiol, with estradiol being the primary form in premenopausal women
[14]. A receptor for estradiol (ERa) was first reported in 1962 [15], with discovery of a
second subtype,

ER~ ,

following in 1996 [16]. Estradiol binding to ERa results in a

conformational change that activates the receptor, leading to its dimerization.

Upon

formation of a dimer, ERa translocates to the nucleus wherein it binds to estrogen
response elements (EREs) in target gene promoters (Figure 1) [17,18]. ERa can also
bind to DNA through a tethering mechanism, wherein a transcription factor such as AP-l,

e.g., c-JunJFos, binds to specific target sequences and ERa then binds through proteinprotein interaction with AP-l [19,20].
between ERa and Spl [21,22].

Such a tethering mechanism can also occur

Binding of ERa and associated coactivators, e.g.,

members of the SRC family or CBP/p300, leads to recruitment of RNA polymerase II for
transcription initiation [21,23].

Work by Carroll and Brown using chromatin

immunoprecipitation (ChIP)-sequencing (ChIP-seq) technology has identified a large set
of estrogen-responsive genes, and expanded understanding of ERE location to include
sequences present in far upstream enhancer regions which exert their influence on target
gene transcription through complex chromatin looping [24,25]. Many identified ERa-
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responslve genes have roles involved in cell proliferation and survival, cell cycle
progression, growth factor signaling, and hormone synthesis [26].

ER~

functions in

much the same way to bind to target gene DNA and promote gene transcription. ERa
and

ER~

share many EREs in common, though ERa takes preference in binding if both

receptors are activated by ligand [27,28] . ERa and

ER~

are both activated by estradiol

binding; however, there have been receptor-selective endogenous ligands, e.g, 5aandrostane-3p,17p-diol

(3 ~-Adiol),

hydroxyphenyl)propionitrile (DPN) for

and
ER~

synthetic

ligands,

e.g.,

identified [29,30] . ERa and

ER~

2,3-bis(4may also

recruit different coactivators, or corepressors instead of coactivators, resulting in
alterations in their effects on downstream gene expression [29,31].
proliferative activity of ERa,

ER~

Rather than the

has been reported to playa growth inhibitory role in

many cell types [29,32].
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Peripheral tissue/breast stromal cells

[Testosterone 1
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CYP19A1
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Figure 1. Model of estrogen action in the breast and inhibition by aromatase
inhibitors and antiestrogens.
In breast cells, estradiol binds ERa leading to its dimerization and subsequent DNA
binding in the cell nucleus to regulate target gene expression [17,21]. The antiestrogens
tarnoxifen and fulvestrant inhibit estradiol binding to ERa. Binding of the selective
estrogen receptor modulator (SERM) tamoxifen to ERa leads to inhibition of coactivator
recruitment and target gene expression [33]. Binding of the selective estrogen receptor
downregulator (SERD) fulvestrant results in altered ligand binding domain structure,
decreased ERa dimerization, and increased proteasomal degradation [34]. Aromatase
inhibitors (AI) inhibit estrogen action in the breast by decreasing the conversion of the
androgens testosterone and androstenedione to estrogens in peripheral tissues and breast
stromal cells by inhibiting the enzyme activity of aromatase (CYP179A1) [35]. Estradiol
has higher affinity for ERa than estrone [16] and these two estrogens are interconverted
by 3P-hydroxysteroid dehydrogenase (3P-HSD) [36]. Androstenedione and testosterone
can also be interconverted by 3P-HSD (not pictured) [36].
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BREAST CANCER TREATMENT
Since the early 1930s when estrogen was first shown to promote breast cancer
formation in mice [37], targeting estrogen signaling has been of interest in the treatment
and prevention of breast cancer. In 1971, Jensen demonstrated that breast cancers with
higher ER content exhibited a greater response to endocrine ablation than ER - cancers
[38]. Studies such as these paved the way to the use of modem antiestrogen therapies to
target the proliferative action of estrogen in breast cancer. Selective estrogen receptor
modulators (SERMs) such as tamoxifen (TAM) and raloxifene (RAL) exert
antiproliferative effects on breast cancer by competing with estrogens for binding to
ERa (Figure 1). First developed as the contraceptive ICI 46,474 [39,40], tamoxifen acts
as a cell type-specific agonist/antagonist of the estrogen receptor (agonist in utems and
antagonist in breast) [33].

Binding of 4-hydroxytamoxifen, the active metabolite of

tamoxifen, to the ligand binding domain (LBD) of ERa results in a repositioning of ERa
helix 12 to cover the hydrophobic coactivator binding groove, preventing binding with
coactivators [41] and resulting in an antagonist function in the breast. In other tissues,
the increased expression of coactivators such as SRC-1 [42] or the presence of other
tissue-specific pathways, as well as promoter-specific functions, allows tamoxifen to
function as an agonist [43,44]. Treatment with tamoxifen leads to inhibition of cell cycle
progression and induction of apoptosis in breast cancer cells [45,46] . The agonist activity
of tamoxifen in the utems leads to an increased risk of endometrial cancer [47].
Tamoxifen has greatly increased the survival rate of breast cancer patients since its initial
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FDA approval in 1977 for the treatment of metastatic breast cancer, resulting in a 32%
reduction in annual death rate [48-50].
Another method of targeting the estrogen receptor is through Selective Estrogen
Receptor Downregulators (SERD) such as the pure antiestrogen fulvestrant (ICI
182,780), which is a steroidal 7a-alkylsulphinyl analogue of estradiol (Figure 1) [34].
Binding of fulvestrant to ERa results in increased ERa turnover by the 26S proteasome
[51]. Reducing the level of ERa blocks estrogen action on target genes in breast cancer
[34].
Other treatment options for breast cancer patients with ERa+ tumors include the
use of aromatase inhibitors (AIs) [35], first proposed in 1973 [52]. In postmenopausal
women, the ovaries no longer produce estrogens and progestins. Instead, estrogens are
produced via the conversion of the androgens androstenedione and testosterone present
in circulation from the adrenals by aromatase located in peripheral tissues, including
stromal cells in breast tissue, to estrogens: estrone and estradiol, respectively by the
enzyme aromatase (CYPI9Al) (Figure 1) [36,53,54].

Aromatase inhibitors such as

exemestane, letrozole, and anastrozole work by inhibiting CYP19Al to stop the
production of estrogens. In a five year study of 8,010 women, treatment with letrozole
resulted in improved disease-free survival, overall survival, and time to distant recurrence
for postmenopausal women, as compared to treatment with tamoxifen or a sequence of
tamoxifen and letrozole [55], highlighting the clinical efficacy of aromatase inhibitors as
a treatment of choice in postmenopausal women.
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MECHANISMS OF ENDOCRINE RESISTANCE

Despite the initial efficacy of antiestrogen treatment, approximately 40% of
patients relapse and die from metastatic disease because the cancer cells become
endocrine-resistant [56].

This sequela is called acquired endocrine resistance smce

patients first respond and then relapse. Five years of tamoxifen therapy results in a
33.2% probability of recurrence at 15 years [49]. Many potential causes of endocrine
resistance have been identified.

Altered expression of ERa itself was identified to

account for only 15-20% of acquired endocrine resistance [57], demonstrating that
mechanisms other than direct loss of the antiestrogen target contribute to endocrineresistant phenotypes.

A variant form of ERa, ERa36, has also been implicated in

tamoxifen resistance, as ERa+ women receiving tamoxifen treatment who also had
increased expression of ERa36 had shorter disease-free survival [58].

Altered coregulator expression

A proper coactivator/corepressor ratio is necessary for basal estrogen-regulated
gene expression.

Increased coactivator or reduced corepressor expression or altered

function has been implicated in endocrine resistance.

Overexpression of coactivator

SRC-3 has been identified in breast cancer and is correlated with reduced responsiveness
to tamoxifen therapy [59,60]. In endocrine-resistant LY2 breast cancer cells, treatment
with tamoxifen increased nuclear co localization of both SRC-l and SRC-3 coactivators
with ERa, indicating tamoxifen instead acts as an ERa agonist rather than antagonist in
these cells [61]. Further, tamoxifen treatment itself can increase the expression of SRC-l
and SRC-3, promoting increased endocrine resistance [62]. The corepressor NCoR is
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downregulated in a mouse model of progression to tamoxifen resistance [63]. Reduced
NCoR expression was also found to be associated with shorter relapse-free survival of
patients treated with tamoxifen [64].

In contrast, no correlation between the

NCoR2/SMRT corepressor and recurrence was found through immunohistochemical
(rnC) staining of breast tumors from tamoxifen-treated patients [65]. SMRT expression
was instead correlated with shortened time to recurrence in untreated patients, suggesting
a different role for this corepressor, such as in inhibition of the activity of transcription
factors other than ERa [65].

Increased kinase signaling

Nongenomic ER signaling can occur via plasma membrane (PM)-associated
forms of ER which, when activated by ligand, stimulate rapid cellular responses through
subsequent effects on downstream kinase activation [66-70]. ERa localization to the PM
may be mediated through palmitoylation at cysteine 447 leading to interaction with
caveolin-1 at lipid rafts (caveolae) in a ligand-independent manner [71,72]. Increased
localization of ERa and a shorter splice variant ERa46 in lipid rafts occurs with HER2
overexpression, and ERa colocalizes with HER2 in MCF-7 cells [73] . In addition to
HER2, PM-associated ERa interacts with other growth factor receptors/receptor tyrosine
kinases (RTKs) such as EGFR and IGFR [74,75]. Elevated EGFR and HER2 expression
has been reported in tamoxifen-resistant breast cancer cell lines, leading to downstream
activation of the ERK pathway [76]. Increased expression of the coactivator SRC-3 and
HER2 enabled tamoxifen to switch to an agonistic effect in breast cancer cells, recruiting
ERa coactivators and stimulating cell proliferation [77]. Activation of EGFR and HER2
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signaling can also promote cell proliferation independent of the involvement of ER,
creating a mechanism for cells to bypass the normal inhibitory effects of tamoxifen and
other antiestrogens [78].
Kinases other than RTKs also have roles in progression to tamoxifen resistance.
Protein kinase C (PKC) activation is known to increase cell proliferation [79]. Elevated
PKCa expression was detected in breast cancer cell lines that have undergone
progression to tamoxifen or fulvestrant resistance, and treatment with a PKC inhibitor
reduced cell proliferation [80]. Knockdown of PKCa expression with shRNA was able
to restore cell sensitivity to tamoxifen but not fulvestrant, suggesting the involvement of
other pathways [80]. Ligand-activated ER can interact with PI3K to activate Akt and
lead to subsequent signaling [81]. Reciprocally, Akt can phosphorylate ERa at serine
167 to lead to ERa activation independent of ligand binding [82]. Tamoxifen can also
activate Akt through phosphorylation at Serine 473 in ER+ breast cancer, which may play
a further role in the contribution of Akt to tamoxifen resistance [83]. Inhibition of Akt
with a PI3K inhibitor increased apoptosis in response to tamoxifen treatment [83].

Altered transcription factor expression/signaling

The nuclear receptor superfamily includes ligand/steroid activated receptors, such
as ER, that act as transcription factors to modulate target gene expression. Alteration of
nuclear receptor signaling has been implicated in development of many types of cancer,
including breast cancer [84] . Muscat et al. recently demonstrated expression of nuclear
receptors COUP-TFII (gene name NR2F2) , thyroid hormone receptor
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~

(TRf3) ,

peroxisome proliferator-activated receptor y (PPARr) , and mineralocorticoid receptor
(MR) to be predictive of metastasis-free survival in tamoxifen-treated patients [85] .

Activation of the inflammatory NFKB pathway leads to increased expression of
genes involved in cellular processes such as proliferation, apoptosis resistance, and other
oncogenic functions [86]. Several groups have reported an association between increased
NFKB pathway activation and tamoxifen resistance [87-92]. Elevated expression of one
or more of the five subunits that comprise the NFKB transcription factor homodimer or
heterodimer has also been reported, including upregulation of RelAlp65 in tamoxifenresistant breast cancer cell lines LCC9 and MCF-7IRR [87,88] and increased RelAlp65
and NFKBlIp50 in a estrogen-independent breast cancer cell line LCCI [93].
Increased AP-l DNA binding was observed in a fulvestrant-resistant breast cancer
cell line [94] as well as in a set of ERa+ tamoxifen-resistant human breast tumor samples
[20], suggesting AP-l may provide an alternative pathway for transcription in the
presence of antiestrogens. Increased activity of the

C-Jlill

NH2-terminal kinase (JNK),

which phosphorylates and activates AP-l , was also identified in tamoxifen-resistant
human breast tumors [20]. In addition, overexpression of

C-Jlill,

a member of the AP-l

heterodimer, rendered MCF-7 cells unresponsive to endocrine therapy [95].

Dysregulated microRNA expression

MicroRNAs (miRNAs) are short, noncoding RNAs of 19-25 nucleotides in length
that downregulate gene expression post-transcriptionally via binding to the 3'UTR of
target mRNAs in a sequence-dependent marmer leading to degradation or inhibition of
translation. Altered expression of miRNAs in cancer has been widely reported, with
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downstream targets in oncogemc systems such as apoptosis, proliferation, cell
differentiation, angiogenesis, invasion, metastasis, and DNA repair [96].

Several

miRNAs have been identified as targeting the expression of ERa, including miR-206
[97] and miR-2211222 [98]. MiR-2211222 was significantly upregulated in tamoxifenresistant breast cancer cell lines and in HER2/neu+ human breast tumor samples [99].
Overexpression of miR-2211222 decreased the sensitivity of cells to treatment with
tamoxifen [98]. Besides targeting ERa, miR-2211222 also targets the cell cycle inhibitor
p27 Kipi [99]. A reduction in p27 Kipi also resulted in decreased growth inhibition by
tamoxifen treatment in breast cancer cells [99] .
In addition to these studies, micro array analysis identified twelve miRNAs that

were differentially expressed between MCF-7 tamoxifen-sensitive and LY2 tamoxifenresistant breast cancer cells [100]. Identified targets of these miRNAs had known roles in
apoptosis (PDCD4 and BCL2),

estradiol metabolism (CfPIBJ),

epithelial to

mesenchymal transition (ZEBl), and growth factor signaling (ERBB3). ERa itself was
also identified as a target in this screen [100].

Altered DNA methylation

Changes in gene promoter methylation can also occur upon progressIOn to
antiestrogen resistance, either through activation of the expression of genes which
promote proliferation through promoter hypo methylation (more common) or via
downregulation of tumor suppressive genes through hypermethylation (less common)
[101]. In one study, tamoxifen-resistant cell proliferation remained ERa-driven, while
fulvestrant-resistant cell proliferation was driven by mechanisms other than ERa [101].
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Many more changes in promoter methylation were found in the fulvestrant resistant cells,
where altered methylation was identified for 72 genes compared to only 10 genes in
tamoxifen-resistant cells [101].

CONCLUSIONS
Most breast tumors are initially driven by estrogens through activation of ERa.
Targeting ERa by SERMs, e.g., tamoxifen, and SERDs, i.e., fulvestrant, and Als, e.g.,
letrozole, have been successful in increasing the overall survival of breast cancer patients
in the last 25-30 yrs [33,48,102]. Unfortlmateiy, -40% of patients relapse on endocrine
therapies [56] and understanding the mechanism by which tumors escape inhibition by
Als, SERMs, and SERDs and re-establishing endocrine-sensitivity is key to enhancing
overall survival. Although many mechanisms have been identified as contributing to the
endocrine-resistant phenotype, the field is currently lacking clinically relevant biomarkers
and functional drug targets. More work is necessary to fully elucidate the complexity of
interactions between the current observations and translate these findings into a unified
model of the endocrine-resistance.
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CHAPTER II - MULTIPLE ROLES OF COUP-TFII IN CANCER INITIATION
AND PROGRESSION

The text of this chapter was published in Journal of Molecular Endocrinology 49(3):
R135-48,2012. doi:1O.1530/JME-12-0144

INTRODUCTION

Steroid hormones and nuclear receptor ligands play critical roles in cancer
initiation and progression and their antagonists have proven efficacy in the treatment and
prevention of cancers. This is most notable in breast and prostate cancers and the use of
all-trans retinoic acid for acute promyelocytic leukemia [103,104].

Steroid/nuclear

receptors act as ligand-activated transcription factors to either positively or negatively
regulate gene expression [84,105] .

Activation of nuclear receptors occurs through

binding a variety of ligands including hormones and vitamins/retinoids.

Nuclear

receptors (NR) have physiological roles to modulate gene expression during development
and growth. As alteration of basal gene expression leads to many pathogenic outcomes including cancer, maintenance of normal gene expression by nuclear receptors is vital.
One such critical nuclear receptor is chicken ovalbumin upstream promoter transcription
factor II (COUP-TFII). From the time of the identification of the COUP-TF family in
1986 [106], the many functions of COUP-TFs have continued to be explored. The role of
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COUP-TFII in cancer is widely debated with evidence linking COUP-TFII to both tumor
suppressive and oncogenic functions. This review will explore both the regulation and
function of COUP-TFII and its connections to cancer.

COUP-TFI AND COUP-TFII
The COUP-TF family consists of two highly homologous subtypes, COUP-TFI
and COUP-TFII, located on human chromosomes 5 and 15, respectively (Figure 2).
COUP-TFs have been previously reviewed [107,108], but not in the specific context of
separating COUP-TFI and COUP-TFII in cancer. COUP-TFs are ancient NRs and are
located close to retinoid X receptors (RXRs) in the evolutionary tree [109,110].

As

evolutionarily conserved transcription factors, COUP-TFs have major roles in
development.

The importance of COUP-TFII expression is evidenced by studies

III

knockout mice [111]. Homozygous mutation of COUP-TFII leads to embryonic lethality
due to impaired angiogenesis and heart defects, resulting in hemorrhage and edema.
These effects may in part be explained by the reduction in angiopoietin-1 expression in
COUP-TFII-null mice [111]. Other important embryonic roles for COUP-TFII include
regulation of limb growth and muscle development [112] . COUP-TFII-null mice display
a reduction in expression of Lbxl, a protein required for proper muscle precursor cell
migration, and in myogenin, which is necessary for muscle cell differentiation [112,113].
Based on the high sequence identity in their DNA binding domains DBDs (Figure
2), we anticipate that COUP-TFI and COUP-TFII regulate the same genes. However,
this has not been empirically tested and it is worth noting that the N-terminus is divergent
(Figure 2) and immunoprecipitation studies indicate differences in proteins interacting
with COUP-TFI [114] and COUP-TFII [115], although, again, this has not been
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Figure 2. Comparison of COUP-TFI and COUP-TFll protein homology.
COUP-TFI (NP_005645.1) and COUP-TFII (NP_066285. 1) amino acid sequences were
obtained from the National Center for Biotechnology Information. The COUP-TF DNA
binding domains (DBD) and ligand binding domains (LBD) share 99% and 97% amino
acid homology, respectively. Positions noted as important in coactivator recognition are
shown in orange.
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systematically studied in cells in which both are expressed. COUP-TFI and COUP-TFII
may have divergent functions in certain contexts as well. Differences in COUP-TFI and
COUP-TFII function in breast cancer endocrine sensitivity, for example, have also been
identified [116]. This review will focus specifically on COUP-TFII.

COUP-TFII REGULATION OF GENE EXPRESSION

Mechanisms of regulation

COUP-TFII can activate or repress gene expression in both a tissue-specific and
gene-specific manner through mechanisms involving direct binding to DNA response
elements or binding to other transcription factors. Through binding to 5' -AOGTCA-3'
direct repeats (DR) with variable spacing [117], COUP-TFII modulates the expression of
target genes.
retinoic

acid

Specific genes upon which COUP-TFII activates transcription include
receptor

~2

(RAR~2,

RARB2)

[115,118],

phosphoenolpyruvate

carboxykinase (PEPCK, PCKl) [119], NGFI-A [120,121], and cholesterol 7ahydroxylase (CYP7Al) [122]. COUP-TFII action may be potentiated by interaction with
coactivators such as steroid receptor coactivator family members SRC-1/NCOAl, SRC2/NCOA2, and SRC-3INCOA3 [120,121], as well as PGCla [120], p300lCBP [121],

orphan receptor coactivator (ORCA) [123], and nucleolin [115] . DNA binding of COUPTFII can promote the binding of a second transcription factor, further activating gene
transcription. This occurs for both the PEPCK and CYP7 Al genes, where COUP-TFII
binding to the promoter recmits binding of glucocorticoid receptor (OR) to enhance gene
expression [119,124]. COUP-TFII can also bind to Spl sites to cooperatively activate
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gene expression, as was reported for regulation of Otx2 expression during morphogenesis
in the mouse eye [125].
Alternatively, binding of COUP-TFII to DRs may result in repression of gene
expression.

In the mechanism of "active repression," COUP-TFII binding results in

recruitment of corepressors, i.e., nuclear corepressor (NCoR) [126] and silencing
mediator of retinoid and thyroid receptors (SMRT) [127,128], resulting in repressed
chromatin structure and a corresponding blockade of target gene transcriptional
activation.

COUP-TFII interaction with SMRT represses PPARyl and PPARY2

expression to suppress adipogenesis [128]. Repression of the human oxytocin promoter
by COUP-TFII binding has also been reported [129].

COUP-TFII represses Pax2

expression in the retina via binding to a DRI site (TGTTCACAGTCCA) [125].
Through an alternative mechanism of transrepression, COUP-TFII can interact
with other nuclear receptors and transcription factors to inhibit their normal
transcriptional activity. Examples of this include inhibition of ER- and GR-induced gene
expression in a gene-specific manner [119,130].

COUP-TFII can also repress AP-l

signaling through interaction with c-Jun [131]. Interaction of COUP-TFII with Runx2
inhibits osteoblast differentiation via blocking Runx2 binding to the osteocalcin promoter
[132]. Other mechanisms of repression involve the modulation of ER, RXR, PPAR, and
VDR activity by competing for DNA response element-binding or heterodimerization
with the class II heterodimeric partner RXR [133].

Ingenuity Pathway Analysis
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As summarized here, COUP-TFII regulates the expression of diverse gene targets.
Table 1 contains a list of known COUP-TFII targets as identified using Ingenuity
Pathway Analysis (IPA; Ingenuity Systems, www.ingenuity.com). These targets are also
displayed in Figure 3. COUP-TFII has varying effects on expression of other nuclear
receptors and transcription factors.
[134],

HNF-l~

COUP-TFII increased the expression of HNF-la

[135], HNF-4a [136], and

RAR~

[115,118,137], while it decreased the

expression of Oct4 [138,139], Daxl [140], and PPARa [141]. As previously described,
COUP-TFII has well known functions in repressing the transcriptional activity of other
nuclear receptors and transcription factors.

Although COUP-TFII increases HNF-4

expression, other reports highlight the repression of HNF-4 function by COUP-TFII.
Specifically, COUP-TFII decreases transcriptional activation of ALDH2 [142] and retinol
binding protein 2 (RBP2) [143] by HNF-4. The HNF-4 activation of hepatic lipase is
suppressed by COUP-TFII [144], while lipoprotein lipase expression is induced by
COUP-TFII synergistically with PPARr [145] ; part of the many of reported functions of
COUP-TFII in the cholesterol processing pathway.

A similar response occurs for

apolipoproteins A-I, A-IV, and C-III, where COUP-TFII represses the RXRa-mediated
expression of APOA-I [135,146,147] and HNF4-mediated expression of APOA-IV
[148,149] and APOC-III [134,135,150,151]. HNF-4 and COUP-TFII binding to the sex
hormone binding globulin (Shbg) promoter was reported in murine Sertoli cells [152].
SHBG expression is increased by HNF-4 and suppressed by COUP-TF in HepG2
hepatoblastoma cells [153].

Decreased SHBG expression is indicative of metabolic

syndrome and may result in increased plasma androgen and estrogen levels, though the
precise connection of COUP-TFII to these phenotypes has not been investigated [154].
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Although COUP-TFII is classically known for.its role in transrepression, COUPTFII may also enhance the effect of a second nuclear receptor. Induction of cytochrome
P450 family members cholesterol 7a-hydroxylase CYP7 Al [122] and aldosterone
synthase CYPllB2 [155,156] by COUP-TFII was reported, with COUP-TFII and HNF-4
acting to synergistically activate CYP7Al [122]. CYP7Al catalyzes the first step in the
conversion of cholesterol to bile acid [122], while CYPIIB2 catalyzes the final steps of
aldosterone synthesis [155], implying that COUP-TFII transcriptional activation would
increase the production of bile acid and aldosterone.
As shown in Table 1 and Figure 3, COUP-TFII opposes PPARylRXR activation
of PEPCK transcription in predadipocytes/fibroblasts, a result that was proposed to
suppress adipogenesis [157]. COUP-TF also inhibited 9-cis retinoic acidlRXR-induced
activation of the lactotransferrin promoter in transiently transfected ZR-75-1 and Hs578T
breast cancer cells apparently by competing for DNA binding to a composite RAREIERE
in the gene promoter [158].

Concurrent binding of COUP-TFII and NF-Y to the

hemoglobin epsilon promoter leads to a repression of gene expression [159]. In addition
to the targets identified by lP A, COUP-TF was reported to playa dual regulatory role in
the transcriptional regulation of the mitochondrial HMG-CoA synthase gene: alone
COUP-TFI stimulated reporter gene activity from the HMG-CoA synthase promoter in
transiently transfected HepG2 human hepatoma and rat Leydig tumor R2C cells, but it
inhibited PPARa-stimulated transcriptional activity by competing for the same DNA
binding site [160].
Some of the lPA-identified COUP-TFII target gene relationships and mechanisms
remain to be fully elucidated. In a study of the transcriptional regulation of murine
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Figure 3. COUP-TFll (NR2F2) target genes.
COUP-TFII has been reported to modulate the expression ofa variety of target genes
both positively and negatively. A list of COUP-TFII target genes and corresponding
network pathway were generated using Ingenuity Pathway Analysis (IP A; Ingenuity
Systems, www.ingenuity.com).
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Table 1. List of COUP-TFII-regulated genes identified by Ingenuity Pathway
Analysis
Gene
(protein)

Name

ALDH2

Aldehyde dehydrogenase 2 family
(mitochondrial)

ANGPT1

Angiopoietin 1

APOA1

Apolipoprotein A-I

APOM

Apolipoprotein A-IV

APOC3

Apolipoprotein C-1I1

CYP11B2

CYP7A1

Aldosterone synthase, cytochrome
P450, family 11 , subfamily B,
polvpeptide 2
Cholesterol 7 alpha-hydroxylase,
cytochrome P450, family 7,
subfamily A, polypeptide 1

Location

Family

Regulation
by COUPTFII

Cytoplasm

Enzyme

Decrease

[142]

Growth factor

Increase

[111]

Transporter

Decrease

[135,146,147]

Transporter

Decrease

[148,149]

Transporter

Decrease

[134,135,150,
151]

Cytoplasm

Enzyme

Increase

[155,156]

Cytoplasm

Enzyme

Increase

[122]

Transcription
reQulator
Transporter

Decrease
sUQQested
Decrease

Extracellular
Space
Extracellular
Space
Extracellular
Space
Extracellular
Space

GATA6

GATA binding protein 6

Nucleus

HBE1

Hemoglobin , epsilon 1

Cytoplasm

HNF1A

HNF1 homeobox A

Nucleus

HNF1B

HNF1 homeobox B

Nucleus

HNF4A

Hepatocyte nuclear factor 4, alpha

Nucleus

KDR

VEGFR-2; kinase insert domain
receptor (a type III receptor
tyrosine kinase)

Plasma
Membrane

L1PC

Lipase, hepatic

LPL

Lipoprotein lipase

LTF

Lactotransferrin

NPPA

Natriuretic peptide A

NROB1

Dax1 , nuclear receptor subfamily
0, group B, member 1

NR1H4
NR112
NR5A2

FXR, nuclear receptor subfamily 1,
group H, member 4
PXR , nuclear receptor subfamily 1,
Qroup I, member 2
LRH-1, nuclear receptor subfamily
5, group A, member 2

Extracellular
Space
Cytoplasm
Extracellular
Space
Extracellular
Space
Nucleus
Nucleus
Nucleus
Nucleus

NRP1

Neuropilin 1

Plasma
Membrane

PCK1

Phosphoenolpyruvate
carboxykinase 1 (soluble)

Cytoplasm

POU5F1

Oct 4; POU class 5 homeobox 1

Nucleus

PPARA

Peroxisome proliferator-activated
receptor alpha

Nucleus

RARB

Retinoic acid receptor, beta

Nucleus

RBP2

Retinol binding protein 2, cellular

Cytoplasm
Extracellular
Space

SHBG

Sex hormone-binding globulin

SLC9A1

Solute carrier family 9, subfamily A
(NHE1 , cation proton antiporter 1),
member 1

Plasma
Membrane
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Reference

[161]
[159,162]

Transcription
regulator
Transcription
reQulator
Transcription
regulator

Increase

[134,161J

Increase

[135]

Increase

[136]

Kinase

Decrease

[163]

Enzyme

Decrease

[144J

Enzyme

Increase

[145J

Peptidase

Decrease

[158J

Other

Increase

[164]

Ligand-dependent
nuclear receptor

Decrease

[140]

Unknown

[161J

Unknown

[161J

Unknown

[161J

Decrease

[163J

Decrease

[157]

Ligand-dependent
nuclear receptor
Ligand-dependent
nuclear receptor
Ligand-dependent
nuclear receptor
Transmembrane
receptor
Kinase
Transcription
reQulator
Ligand-dependent
nuclear receptor
Ligand-dependent
nuclear receptor

Decrease

[138,139J

Decrease

[141]

Increase

[115,118,137,
1431

Transporter

Decrease

[143J

Other

Decrease

[152,153J

Ion channel

Increase

[165J

hepatic development, COUP-TFII occupancy of GATA-6, FXR, PXR, and LRH-J
promoters, as determined by chromatin immunoprecipitation (ChIP) assay, was reported
during the postnatal period [161]. While an inhibitory relationship was suggested for the
effect of COUP-TFII on GATA-6, the effect on FXR, PXR, and LRH-J expression is not
yet known [161].

Several other target genes have been identified that highlight the

critical function of COUP-TFII in the vascular system. These include an increase in
angiopoietin 1 [111] and natriuretic peptide A [164] by COUP-TFII, and a decrease in
VEGFR-2 and neuropil in 1 [163]. COUP-TFII enhances expression of the NHE1 solute
exchanger [165,166].
In summary, as indicated by the IPA (Figure 3) and consistent with previous

reports, COUP-TFII plays a role in many downstream pathways and may either activate
or suppress gene expression.

Role in the retinaic acid pathway

COUP-TFs are classified as orphan members of the NR superfamily, because
their endogenous ligand(s) is not known. However, Kmse et al demonstrated in silica
binding of all-trans (atRA) and 9-cis (9cRA) retinoic acid to the crystal stmcture of the
COUP-TFII LBD [120].

RA released the COUP-TFII LBD from the autorepressed

conformation. While the investigators did not directly test binding of all-trans or 9-cis
RA to COUP-TFII, they demonstrated that treatment with atRA or 9cRA increased
COUP-TFII interaction with the coactivator SRC-3, with an EC so of

1O-30~.

In

agreement with this data, addition of 20 /-lM atRA or 9cRA led to COUP-TFII' s
activation of a NGFI-A-luciferase reporter [120]. Although these concentrations of atRA
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and 9cRA are greater than the physiological concentration of these retinoids, this finding
provides novel insight into the ligand binding ability of COUP-TFIL Indeed, the function
of this activation can be seen in the regulation of RAR~2 by COUP-TFII, as COUP-TFII
activation of

RAR~2

expression is increased with the addition of all-trans retinoic acid

[115,118], Treatment of MCF-7 breast cancer cells with atRA also increased COUPTFII-binding to the RARB2 promoter in a ChIP assay [115]. Retinoic acid induces the
expression of COUP-TFII in certain breast cancer cell lines (e.g. T47D and ZR-75) but
not others (e.g. MCF-7 and MDA-MB-231) (Figure 4) [115,167].

This indicates a

potential feed forward loop, as treatment with retinoic acid may increase both the
expreSSIOn and activation of COUP-TFII, with downstream effects on retinoic acid
receptor.

REGULATION OF COUP-TFII EXPRESSION

Tissue-specific regulation in humans

COUP-TFII has a widespread tissue distribution, with detectable expression in
every human tissue type examined [168]. The regulation of COUP-TFII expression is
tissue and cell-type specific, and can be modulated both transcriptionally and posttranscriptionally (Figure 4).

Hyperinsulinemia is a risk for breast cancer [169,170],

COUP-TFII expression was repressed by insulin and glucose in the liver and pancreas of
C57BL6/J mice and in mouse primary hepatic and pancreatic cell culture [1 71].

contrast, we found that insulin treatment had no effect on COUP-TFII expression in
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Figure 4. Regulation of COUP-TFII expression.
COUP-TFII expression has been shown to be modulated both transcriptionally and posttranscriptionally by a variety of transcription factors, signaling pathways, and various
molecules, as diagramed here.
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Figure 5. Insulin treatment does not affect COUP-TFII expression in human breast
cancer cells.
MCF-7 and T47D human breast cancer cells were grown as in described in [115] . As
T47D growth medium contains 6 mg/ml insulin, T47D cells were either grown in normal
medium (with insulin) or in insulin-free medium to determine if this affected outcome.
Prior to treatment with insulin, all cells were "starved" in low glucose medium (5 mM
glucose) for 24 h [136,171]. Cells were treated for 6 h with the indicated concentrations
of insulin. QRT-PCR was performed to measure NR2F2 expression relative to GAPDH
as a reference gene, as described in [115]. Insulin treatment had no statistically
significant effect on COUP-TFII expression in these cell lines.
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MCF-7 and T47D breast cancer cells (Figure 5). The lack of alteration in COUP-TFII
expression with insulin in breast cancer cells highlights the importance of cell-specific
regulation of COUP-TFII expression. There are currently no reports on the effect of
insulin on COUP- TFII expression in other cancers.

miRNA regulation

MicroRNA (miRNA) expression is altered in a variety of conditions and disease
states, including cancer, and results in important post-transcriptional regulation of crucial
proteins

[96].

While

115

miRNAs

are

predicted

to

target

NR2F2

(http://cometa.tigem.it/site/index.php), only one miRNA has been verified. rniRNA-302
directly represses COUP-TFII expression in human embryonic stem cells [138].
Regulation of COUP- TFII expression by miRNA has not yet been reported in cancer
cells.

DNA methylation

Methylation at CpG islands can result in suppression of gene transcription, and is
known to be a hallmark of cancer progression. DNA methylation may also occur at
intragenic and intergenic sites, as well as at the promoter [172,173]. Specifically, COUP-

TFII has been found to be methylated in many cancers, including mantle cell lymphoma,
acute myeloid leukemia,

salivary gland adenoid cystic carcinoma, pancreatic

adenocarcinoma, colon cancer, breast cancer ductal carcinoma in situ, as well as a
tamoxifen-resistant breast cancer cell line [101,174-179]. NR2F2 gene hypermethylation
was associated with a concordant reduction in rnRNA expression in mantle cell
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lymphoma, pancreatic cancer, and tamoxifen-resistant breast cancer cells [101,174,177].
Whether this indicates a general trend of reduced COUP-TFII expression due to
epigenetic modification across cancer types remains to be seen.

Contrary to these

reports, high levels of COUP-TFII mRNA expression were found in all cell lines in the
NCI60 panel of human cancer cell lines [180].

Regulation by other transcription factors

COUP-TFII and Ets-l have overlapping expression patterns in mesenchymal cells
of the mouse gut, spleen, lungs, and other tissues [181]. Members of the ETS family
(Ets-l, Ets-2, ETV, PEA3, Spi-l, and ERM) increased murine COUP-TFII-promoter
activity in HeLa cells.

Steroid receptor coactivators SRC-IINCOAl, TIF2/SRC-

2INCOA2, and RAC3/SRC-3INCOA3 enhanced the activation of the COUP-TFII

promoter [181]. In agreement with this data, SRC-3 and RARa increased COUP-TFIIpromoter activity in HepG2 human hepatocellular carcinoma cells with atRA treatment.
Reciprocally, siRNA knockdown of SRC-3 repressed COUP-TFII expression [182]. We
observed that the protein expression (by immunohistochemical staining) of AIB lISRC3/NCOA3, PEA3 , and SRC-IINCOAI were correlated with COUP-TFII in breast cancer

patient samples [115].

Regulation by altered kinase activity and other signaling pathways

Several factors were reported to alter COUP-TFII expression in pathogenic states.
More et al reported that expression of COUP-TFII, but not COUP-TFI, is stimulated by
activation of the MAP kinase (MAPK) pathway. Breast cancer cell lines with increased
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MAPK activity, i.e., SKBR3, had a concomitant increase in COUP-TFII expression
[183]. In contrast to the idea that MAPK activation increases COUP-TFII expression,
MAPK has also been shown to phosphorylate and inactivate PP2A (protein phosphatase
2A), leading to a suppression of COUP-TFII expression in human peripheral blood
CD34+ cells [184]. Inactivation of PP2A also inhibits sonic hedgehog-induced COUPTFII expression in P19 cells [185] . PP2A is inhibited by the FOXO transcription factors,
including FOXOI [186]. COUP-TFII expression is induced by FOXOI in pancreatic
beta cells and hepatocytes [171], highlighting the highly cell type-specific nature of these
pathways.

MAPK activity may lead to increased COUP-TFII expression in certain

conditions, while it may alternatively repress COUP-TFII in others. Taken together,
these data suggest a possible feedback loop in certain cell types (Figure 4).
In addition to MAPK activation, Notch signaling is also dysregulated in many

types of cancer. Increased Notch signaling has been implicated in carcinogenesis and
metastasis and is also involved in regulation of endothelial cell proliferation and
angiogenesis [187,188]. In breast cancer, Notch and its ligand Jaggedl upregulate the
expression of Slug, a transcriptional repressor of E-cadherin important in metastatic
progression [189].

Notch signaling has also been implicated in the amplification of

HER2 and survival of tumor initiating cells [190] and cancer stem cells [188,191,192].
Activation of the Notch pathway confers cancer-like properties and apoptosis-resistance
to normal breast epithelial cells [193]. Regulation of COUP-TFII by Notch signaling has
been reported in endothelial cells of both arterial and venous origin and in mouse studies
[163,194,195]. Notch can suppress COUP-TFII and Pro spero-related homeobox domain
1 (Proxl), leading to an arterial rather than lymphatic phenotype in endothelial cells
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[163,194,196]. COUP-TFII, in turn, can also suppress Notch signaling to result in vein
rather than artery formation [195]. Transforming growth factor-~l (TGF~l) suppresses
COUP-TFII expression in keratinocytes and fibroblasts leading to induction of collagen
type VII (COL7Al) expression [197] and in vascular progenitor cells to negatively
regulate lymphvasculogenesis [198]. Whether COUP-TFII is regulated via Notch and
TGF~l

signaling has not yet been explored in cancer.
Amplification of

[199]. In normal tissues,

Wnt/~-catenin
~-catenin

signaling has been widely reported in cancer

signaling is controlled through signals leading to its

phosphorylation by a multiprotein destruction complex and subsequent degradation. In
breast and other cancers, increased expression of Wnt ligands leads to maintenance of ~
catenin activation by preventing its degradation [199].

~-catenin

signaling has many

outcomes, such as normal mammary morphogenesis and ductal maturation; however,
sustained activation, through a variety of mechanisms, leads to carcinogenesis [199].
ChIP assays demonstrated that

~-cateninJTCF7L2

(T-cell factor 7-like 2 or transcription

factor 7-like 2) bind the promoter of COUP-TFII to activate expression, resulting in
suppression of adipocyte differentiation [128]. COUP-TFII is expressed in mouse liver
and pancreatic

~-cells

and plays roles in the maintenance of glucose homeostasis and

insulin sensitivity [171,200]. Boutant et at also reported that

~-cateninlTCF7L2

induces

COUP-TFII expression in the pancreas, and that COUP-TFII expression was necessary
for normal

~-cell

function and glucose tolerance in mice [201]. The influence of

catenin signaling on COUP-TFII expression in cancer has yet to be examined.

30

~

ROLE OF COUP-TFII IN CANCER

Angiogenesis

Many studies of COUP- TFII involve its regulation of the angiogenesis pathway.
Under normal conditions, angiogenesis is not active after the time of vasculature
development during embryogenesis. However, upon progression of a tumor's growth,
activation of angiogenesis leads to the formation of new blood vessels to support the
tumor [202]. COUP-TFII is necessary during normal development for angiogenesis and
lymphangiogenesis, as evidenced by the impaired vessel formation and embryonic
lethality in COUP-TFII knockout mice [111 ,203].

The expression of many pro-

angiogenic factors is modulated by COUP-TFII, including members of the vascular
endothelial growth factor (VEGF) family and their receptors.

VEGF induces

angiogenesis and lymphangiogenesis by activating tyrosine kinase receptors and
upregulates endothelial cell proliferation and migration [204]. In a model of pancreatic
islet tumorigenesis, ablation of COUP-TFII increased VEGFR-l expression, impairing
VEGFR-2 signaling and reducing angiogenesis [205].

Metastasis to regional lymph

nodes was reduced as a result, implying that COUP- TFII may have a pro-angiogenic,
pro-metastatic role in pancreatic cancer [205].

Similarly, ablation of COUP- TFII

decreased tumorigenesis in BI6-FlO melanoma and Lewis lung carcinoma mouse
xenografts, and reduced tumorigenesis and metastasis in a spontaneous mouse mammary
tumor model. These effects were attributed to a decrease in blood vessel density in
COUP-TFII-deficient mice [206].
In addition to regulating VEGFR expression, COUP- TFII can also affect

angiogenesis .via regulation of angiopoetin-l (Ang-l ), through binding to an Spl site in
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the promoter region. The induction of Ang-1 is partially responsible for the effects of
COUP-TFII, as overexpression of Ang-1 allowed for recovery of angiogenesis in COUPTFII-deficient mice [206].
Lymphangiogenesis can also contribute to metastasis by allowing the spread of
tumor cells to lymph nodes [207,208]. COUP-TFII regulates tumor lymphangiogenesis
via inducing expression of VEGF-C and neuropilin-2, a coreceptor for VEGF-C
[203,209]. In a murine model of pancreatic islet tumorigenesis, COUP-TFII deletion
resulted in impaired lymphangiogenesis and reduced metastasis [205]. Concordant with a
role for COUP-TFII in lymphangiogenesis, Kang et al reported that Notch suppresses
COUP-TFII expression, along with Prox1, in human primary dermal lymphatic
endothelial cells to signal for arterial rather than lymphatic differentiation [163].
Suppression of COUP-TFII resulted in an increase in VEGF signaling by activating
expression of VEGFR-2, a VEGF receptor whose signaling can feedback to increase
activation of Notch signaling [163].
COUP-TFII induction by 9cRA was also shown to promote network formation
but not cell fusion in SKBR3 breast cancer cells, suggesting a role in the endothelial
trans differentiation pathway as a necessary part of vascular formation [210].

Taken

together, these data indicate that COUP-TFII may regulate angiogenesis and
lymphangiogenesis, primarily through modulation of VEGF and its receptor in a cell
context-dependent manner.

Invasion and metastasis
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In addition to stimulation of angiogenesis, COUP-TFII may have other distinct
roles in regulation of tumor growth and metastasis. Transfection with COUP-TFII in
A549, H520, and H441 lung cancer cells and MDA-MB-231 breast cancer cells was
reported to increase migration and invasion [211]. Navab et al found that COUP-TFII
upregulated the expression of extracellular matrix-degrading proteinases matrix
metalloproteinase 2 (MMP2) and urokinase-type plasminogen activator (uPA) [211].
MMP2 and uPA are known to play critical roles in cancer, particularly in angiogenesis
and metastasis [212]. High levels of uPA are predictive of recurrence but also of a
favorable response to adjuvant chemotherapy in breast cancer patients [213].
Interestingly, it has also been reported that uPA expression is dependent on Notch
signaling in MDA-MB-231, MDA-MB-468, and HCC1143 breast cancer cells [214].
COUP-TFII and MMP2 expression were also positively correlated in a breast tumor
micro array [115], further indicating a potential relationship between COUP-TFII and
extracellular matrix degradation. In contrast, COUP-TFII decreased cell motility when
transfected into LY2 tamoxifen-resistant breast cancer cells, while having no significant
effect on invasion [116].

Estrogen receptor and clinical outcome

Nagasaki et al demonstrated that COUP-TFII expression was correlated with ERa
status and indices of poor clinical outcome (clinical stage, lymph node status, histological
grade) in human breast tumor samples, indicating COUP-TFII may playa role in cancer
progression [209]. We also found that COUP-TFII and ERa expression were correlated
in a human breast tissue/tumor micro array, but instead noted an inverse relationship
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between COUP-TFII expression and TNM (tumor, node, metastasis) classification [115].
Similar findings were observed at the mRNA level by examining breast tumor rnRNA
transcriptomes in Oncomine [115]. COUP-TFII expression was significantly higher in
ERa+ breast cancer samples and significantly lower in metastatic samples [115]. These
findings indicate a function for COUP-TFII in inhibiting tumor progression. A positive
correlation with ERa is consistent with a previous report that siRNA knockdown of ERa
in MCF-7 breast cancer cells decreased COUP-TFII expression and treatment with
estradiol increased the expression of COUP-TFII [116]. ERa is a positive prognostic
factor in breast tumors and is the target of endocrine-targeted cancer therapeutics such as
the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene [48].
COUP-TFII, but not COUP-TFI, is reduced in tamoxifen-resistant human breast cancer
cells, and re-expression of COUP-TFII can restore tamoxifen-sensitivity [116]. As ERa
expression is important in keeping breast cancer cells responsive to treatment, the
correlation of COUP-TFII and ERa further demonstrates a beneficial role for COUPTFII, highlighting its potential importance in maintaining differentiation and endocrine
sensitivity.
In contrast to a role for COUP-TFII in maintaining antiestrogen sensitivity,

Holbeck et al reported that cancer cells in the NCl60 panel expressing low levels of
COUP-TFII showed higher sensitivity to microtubule-targeting drugs vinblastine,
co1chicines, and taxol [180]. These data demonstrate that both cell type-specific as well
as drug-specific mechanisms may determine the role of COUP-TFII in influencing
treatment response.
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Steroidogenesis

COUP-TFII expression was reported to be high in aldosteroma, with an inverse
correlation to adrenal steroidogenesis [215].

These data also indicated an inverse

correlation between COUP-TFII expression and CYP17Al expression, with COUP-TFII
inhibiting CYP17Al in aldosteroma [215]. COUP-TFII competed with SF-l for binding
to overlapping sites within the promoters of the CYP17Al [216,217], CYPllAl, and
STARDI genes in rat Leydig cells and to suppress testosterone production [216]. COUPTFI and COUP-TFII both repressed angiotensin II-stimulated STARDI (StAR) in bovine
adrenal glomerulosa cells in primary culture [218]. COUP-TFII also competed with SF-l
for the human aromatase P450 promoter II in primary endometriotic stromal cells and
suppressed

aromatase

expression.[219].

Overexpression of SF-l

in primary

endometriotic stromal cells outcompeted the normal protective effect of COUP-TF
(whether COUP-TFI or COUP-TFII was involved was unclear since both were equally
expressed at the mRNA level) resulting in high local aromatase expression in
endometriosis [219]. COUP-TFII was reported to bind the SI silencer region of the
human aromatase gene and suppress transcription in MCF-7 cells [220]. Indeed, the
decreases in COUP-TFI, EARy, EAR-2, Snail and Slug in breast cancer were suggested
to increase aromatase expression [221].

Thus, the downregulation of COUP-TFII

expression that we observed in endocrine-resistant breast cancer cells [116] would be
expected to increase aromatase and thus increase local estrogen production. However,
whether increased COUP-TFII suppresses local androgen or estrogen biosynthesis in
breast tissue is unknown.

Local conversion of adrenal androgens to estrogens by

aromatase is the target of AI therapy for post-menopausal women. However, there are
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androgen metabolites, e.g.,

3~-adiol,

that bypass aromatase which activate ERa and

ER~

and may playa role in AI resistance [222,223]. Overall, the literature supports a negative
role for COUP-TFII in regulating steroid hormone synthesis and further studies
addressing COUP-TFII regulation of aromatase gene expression in local estrogen
production in breast [224] and lung [225] adenocarcinomas would be of merit.

CONCLUSIONS

The studies reviewed here indicate that COUP-TFII is regulated and is
functionally active to regulate target gene transcription in a cell type-dependent manner.
There is evidence that COUP-TFII may perform both pro- and anti-tumorigenic roles.
COUP-TFII has been repolted to increase angiogenesis and lymphangiogenesis, both
increase and decrease tumor metastasis, lead to favorable and unfavorable therapeutic
outcome in cancer therapy, and suppress steroidogenesis. Qin et al reported that COUPTFII was not expressed in tumor cells, but rather was instead found in high concentration
in the surrounding blood vessels that support tumor growth and spread [206].

This

indicates a crucial point of consideration about the nature of COUP-TFII in cancer
formation and progression: the function of COUP-TFII within cancer cells versus in the
surrounding tumor microenvironment and other cell types. Tissue type is clearly an
important determinant in deciphering the oncogenic or tumor-suppressive nature of
COUP-TFII. Many studies published to date involve the regulation and role of COUPTFII during development and in non-cancerous disease states. The full applicability of
these studies to our knowledge of the role of COUP-TFII in carcinogenesis and cancer
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progression remains to be seen. Future studies are necessary to elucidate the complex
nature of this vital nuclear receptor.

DISSERTATION SPECIFIC AIMS AND HYPOTHESES

Despite the initial efficacy of tamoxifen and other antiestrogens, approximately
40% of patients relapse and die from metastatic disease, in part because the cancer cells
become endocrine-resistant [56].

Identification of proteins and pathways key in the

progression to endocrine resistance is essential for the development of improved
treatments for patients. Our lab has previously reported that the expression of COUPTFII, but not COUP-TFI, is reduced upon progression to endocrine resistance, and that
overexpression of COUP-TFII can restore endocrine sensitivity [116]. As reviewed in
chapter 2, many reports on the cellular roles of COUP-TFII are contradictory and fail to
provide insight necessary to understand the mechanism of COUP-TFII action in
endocrine-resistant breast cancer [226].

The overall goal of this study was to identify

and evaluate the function of proteins that interact with COUP-TFII to define the role of
COUP-TFII in breast cancer and endocrine sensitivity. COUP-TFII may be both a useful
biomarker to predict tamoxifen-sensitivity as well as a target to restore endocrine
sensitivity to resistant cells. The overall hypothesis was that the activity of COUP-TFII
in maintenance of endocrine sensitivity and cell differentiation is dependent on its
interacting proteins.
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SPECIFIC AIM 1: Characterize the interaction of COUP-TFII and nucleolin.
I tested the hypothesis that COUP-TFII and nucleolin interact directly in MCF-7 and
T47D breast cancer cells. COUP-TFII and nucleolin interaction was evaluated in MCF-7
and T47D cells through co-immunoprecipitation. In vitro binding was assessed through a
maltose binding protein (MBP) pulldown assay. COUP-TFII and nucleolin expression
were analyzed in human breast cancer patient samples through immunohistochemistry.

SPECIFIC AIM 2: Determine how the interaction of COUP-TFII and nucleolin
affects target gene expression in breast cancer cells.
I tested the hypothesis that nucleolin functions as a coregulator for COUP-TFII in the
expression of the COUP-TFII target gene RARB2. The ability of nucleolin to function as
a coactivator for COUP-TFII was analyzed in MCF-7 and T47D cells.

Transient

transfection, siRNA knockdown, luciferase assays, and other assays were used to
determine the contribution of nucleolin to RARB2 expression.

SPECIFIC AIM 3: Determine if COUP-TFII expression modulates NFKB activity in
endocrine-resistant breast cancer cells.
I tested the hypothesis that COUP-TFII suppresses NFKB activity in breast cancer cells
through a mechanism involving suppression of NFKB transcription. The effect of COUPTFII on NFKB activity was assayed in endocrine-sensitive MCF-7 versus endocrineresistant LCC9 breast cancer cells using luciferase assays and electrophoretic mobility
shift assays (EMSA). NFKB subunit and target gene expression was examined using
QRT-PCR and western blots.
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SPECIFIC AIM 4: Determine the identity of proteins that interact with COUP-TFII

in tamoxifen-treated MCF -7 human breast cancer cells.
I tested the hypothesis that 4-0HT treatment changes the interaction of COUP-TFII with
other nuclear proteins in MCF-7 endocrine-sensitive cells and that these proteins are
important in mediating the ability of antiestrogens to inhibit cell proliferation. MCF-7
breast cancer cells were transiently transfected with FLAG-tagged COUP-TFII and
treated with ethanol (EtOH, vehicle control) or 4-0HT before immunoprecipitation was
performed using a FLAG antibody to capture COUP-TFII and associated proteins. Mass
spectrometry identified proteins interacting with COUP-TFII specifically when treated
with EtOH versus 4-0HT.

Further experiments including co-immunoprecipitation,

transient transfection, western blots, and QRT -PCR were performed to analyze the role of
the identified COUP-TFII-interacting proteins.
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CHAPTER III - IDENTIFICATION AND CHARACTERIZATION OF
NUCLEOLIN AS A COUP-TFII COACTIVATOR OF RETINOIC ACID
RECEPTOR ~ TRANSCRIPTION IN BREAST CANCER CELLS

The text of this chapter was published in PLoS QNE 7(5): e38278, 2012.
doi: 10. 13711joumal.pone.0038278

INTRODUCTION
COUP-TFI (NR2Fl) and COUP-TFII (NR2F2) are 'orphan' members of the
steroid/nuclear receptor (NR) superfamily [107]. COUP-TFs regulate gene transcription
in a cell- and gene- specific manner. COUP-TFII differs from COUP-TFI at the Nterminus, but is conserved within the DNA binding and ligand binding domains (DBD
and LBD) [107]. Gene knockout mice demonstrated that COUP-TFI (Nr2fl) and COUPTFII (Nr2j2) have distinct roles during embryogenesis, notably in the nervous and
cardiovascular systems, respectively [111,227]. Although COUP-TFs are classified as
orphan receptors, as they have no currently established physiological ligands, the crystal
structure of the COUP-TFII LBD showed that its "auto-repressed conformation" was
relieved by 9-cis and all-trans retinoic acids (9cRA and atRA) that bind the LBO with 17-26

~M

affinity [120].
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While the precIse gene changes and epigenetic events that lead to breast
tumorigenesis are still under investigation [228-230], estrogens are well-established risk
factors in breast cancer [231].

Adjuvant endocrine therapies including the use of

antiestrogens, e.g., tamoxifen (TAM), and aromatase inhibitors (AI), e.g., letrozole, are
effective in reducing disease recurrence in many patients [102]. Antiestrogens, including
TAM and fulvestrant, work by targeting estrogen receptor a (ERa) because of its
proliferative activity in breast tumors [232,233]. AI work by blocking the synthesis of
estrogens from androgenic precursors including androstenedione and testosterone [234].
Altered gene expression can dictate both the formation of tumors and patient
response to treatment. In breast cancer, conflicting evidence has been reported on the
nature of COUP-TFII in either promoting or inhibiting cancer formation, as well as
influencing patient survival with adjuvant therapy. COUP-TFII is not expressed in basallike, triple negative, dedifferentiated MDA-MB-231 and is lower in tamoxifen
(T AM)/endocrine-resistant LCC9 and LY2 breast cancer cells than in parental endocrinesensitive MCF-7 cells, whereas COUP-TFI expression is similar [116], suggesting a role
in maintenance of differentiation and endocrine sensitivity. In agreement with this data,
COUP-TFII was reduced in some ERa-null breast cancer cell lines [167]. These results
suggest that, like ERa, loss of COUP-TFII may be considered an indicator of poor
prognosis. Other reports suggested that COUP-TFII may playa role in mammary tumor
formation in mice and that COUP-TFII expression in human breast tumors is associated
with reduced survival [206,209]. These conflicting findings may be resolved through
further investigation of the activities of COUP-TFII in breast cancer.
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The function of COUP-TFs as transcription factors that can either suppress or
stimulate gene transcription is dependent on interactions with other proteins. COUP-TFI
[127] and COUP-TFII [119] interact with corepressors NCoR and SMRT.

Proteins

interacting with COUP-TFI include Sp 1 [235]; the viral transactivator Tat [236]; CTIP1
and CTIP2, HDACs 1 and 2, and a nucleosome remodeling and deacetylation (NuRD)
complex [237]; ERa [130,238]; AhR [239]; and many coregulators (reviewed in [156]).
Twenty-four proteins interacted with HA-FLAG-COUP-TFI in stably-transfected
HeLaS3 cells [114].

Interaction of ORCA with the COUP-TFII LBD stimulated

transcriptional activation of the rat hydratase-dehydrogenase gene promoter in transiently
transfected Bsc40 monkey kidney cells [123].

COUP-TFII interacted with the hinge

domain of the glucocorticoid receptor a (GRa) and repressed phosphoenolpyruvate
carboxykinase gene transcription [124].

No one has, to our knowledge, reported

proteomic identification of COUP-TFII-interacting proteins.
The focus of the present study was to identify proteins that interact with COUPTFII in MCF-7 cells to gain new insights into COUP-TFII' s role in breast cancer.
Nucleolin was identified among the nuclear proteins interacting with COUP-TFII.
COUP-TFII-nucleolin interaction was confirmed by co-immunoprecipitation. This study
reports a significant inverse association of COUP-TFII with breast tumor grade.
Expression of the tumor suppressor retinoic acid receptor P2 (RARP2), reduced in breast
cancer [240,241], and dependent on COUP-TFII [118] was increased by nucleolin
overexpression. Our data indicate that nucleolin plays a coregulatory role in COUP-TFII
transcriptional regulation of RARB2.
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MATERIALS AND J\IlETHODS

Chemicals

4-hydroxytamoxifen (4-0HT) and 9-cis and all-trans retinoic acid (9cRA and
atRA) were from Sigma (St. Louis, MO). ICI 182,780 (Fulvestrant) was from Tocris
(Ellisville, MO). Sequences of AS 141 1 (AGRO 100, an antiproliferative, 26-mer G-rich
oligonucleotide) and an inactive negative control C-rich control oligonucleotide (CRO)
were reported [242] and purchased from Integrated DNA Technologies, Inc. (Coralville,
JA).

Antibodies and reagents

The following antibodies were purchased: polyclonal COUP-TFII (Abcam,
Cambridge, MA); monoclonal (mAB) anti-human COUP-TFII (R&D systems,
Minneapolis, MN; PP-H7147-00. 2ZH7147H); mAB anti-FLAG M2 and

~-actin

(Sigma); polyclonal nucleolin (NB600-241, Novus Biologicals, Littleton, CO),
monoclonal nucleolin/C23 (MS-3; Santa Cruz Biotechnology, Santa Cruz, CA); MBPprobe (R3.2; Santa Cruz Biotechnology); and HDAC-l (Santa Cruz Biotechnology).
HRP-conjugated secondary antibodies were from GE Healthcare (Piscataway, NJ).
Goat anti-rabbit and anti-mouse magnetic beads were from Thermo Scientific
(Waltham, MA). In vitro transcription/translation used PROTEINScript II kit (Ambion,
Austin, TX) or TNT Quick Coupled Transcription/Translation (Promega, Madison, WI).

Plasmid construction
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Human COUP-TFII cDNA was amplified from DNA from MCF-7 cells using Pfx
DNA polymerase (Invitrogen, Carlsbad, CA). The forward primer contained an EcoRI
restriction site (5'-CCGAATTCGATATGGCAATGGTAGTTAGCACG-3') and the
reverse primer was designed to remove the stop codon from COUP-TFII and add a XhoI
restriction site (5'-GTCCTCGAGTCGTTGAATTGCCATATACGGCCA-3').

The

resulting fragment was cloned into pIRES-GFP-1a (Stratagene, Santa Clara, CA) to
constmct a C-terminal FLAG-tagged COUP-TFII expression plasmid (pIRES-COUPTFII-FLAG). The inclusion of COUP-TFII-FLAG in the resulting pIRES-COUP-TFIIFLAG plasmid was verified by DNA sequencing and western blot analysis (Appendix I,
Figure Sl).

Cell culture

MCF-7 and T47D breast cancer cells were purchased from ATCC and used at
passage < 10. T47D were grown in RPMI 1640 (Invitrogen) supplemented with 5% FBS
and 61lg/ml insulin (Sigma). MCF-7 cells were maintained as described [116].

Affinity purification and identification of COUP-TFII-FLAG interacting proteins

One mg of whole cell extract (WCE), prepared as described in [116], from MCF7 cells transfected (24 h) with pIRES-COUP-TFII-FLAG as described in Methods Sl
(Appendix I) was incubated with EZ view™ Red ANTI-FLAG® M2 Agarose Affinity
gel (Sigma) overnight (-16 h) at 4°C with constant rotation.

COUP-TFII-FLAG

interacting proteins were eluted using two methods: 1) 0.1 M glycine, pH 3.5, 15 min at
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room temperature with constant rotation; 2) an additional incubation with 0.1 M glycine,
pH 3.5, 5 min at 95°C (Appendix I, Fig. S2A).

Protein identification by multidimensional protein identification technology (MudPIT)

Proteins eluted from the FLAG-affinity gel were trypsin digested and processed
for mass spectrometry as detailed in Methods S 1 (Appendix I). MSIMS spectra of the
peptides were acquired by Q-TOF mass spectrometer (Waters, Milford, MA) in data
dependent mode. Proteins were identified by comparing MS/MS spectra with sequences
in Swiss-Prot database by ProteinLynx from Waters.

Co-immunoprecipitation (co-IP) and immunoblotting

Nuclear and cytosolic proteins were harvested in lysis buffer (lOmM HEPES pH
7.9, 1.5mM MgClz, and lOmM KCI) containing 0.1 M DTT, protease and phosphate
inhibitors (Roche, Indianapolis, IN).

Following centrifugation, the supernatant

containing cytosolic extract (CE) was collected. The pellet was resuspended in nuclear
extraction buffer (20 mM HEPES pH 7.9, 1.5 mM MgClz, 0.4 M NaCI, 0.2 M EDTA,
and 25% (v/v) glycerol), 0.1 M DTT, protease and phosphatase inhibitors. Nuclei were
disrupted by sonication and the nuclear extracts (NE) were collected after centrifugation.
For IP, 4

~g

COUP-TFII polyclonal antibody, nucleolin monoclonal antibody,

rabbit or mouse IgG (Abeam, Santa Cruz) were added to 250

~l

prewashed MagnaBind

goat anti-rabbit or anti-mouse IgG beads in RIPA buffer (Sigma) containing DTT,
protease and phosphatase inhibitors for 30 min at 4°C. 200-400

~g

NE was added and

incubated for 4 h at 4°C. Antibody-bound beads were incubated with buffer without NE
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as an additional negative control. Beads were washed 2x with RIPA buffer, resuspended
in 1x Laemmli loading buffer (BioRad, Hercules, CA), separated by SDS-PAGE and
analyzed by western blot [116].

In vitro transcribed-translated COUP-TFII interaction with purified recombinant
maltose binding protein (MBP)-nucleolinfusion proteins

Extracts from E. coli expressing MBP-tagged nucleolin constructs, a gift from Dr.
Nancy Maizels [243], were prepared in column buffer (CB, 20 mM Tris-HCI (pH 7.4),
0.2 mM NaCI, 1 mM EDTA) with 0.1 mM PMSF. 200 Ilg crude extract was incubated
with 100 ilL amylose resin (New England Biolabs, Ipswich, MA) for 2 h at 4°C. After
washing with CB, 20 ilL of in vitro transcribed/translated COUP-TFII (pIRES-COUPTFII-FLAG) was added to the amylose resin for 2 h at 4°C. After washing 3x with CB,
bound proteins were eluted with 50 ilL of 1x Laemmli loading buffer.

Immunofluorescence staining of COUP-TFII and nucleolin

MCF-7 cells were grown on culture slides (BD Biosciences, Bedford, MA) and
fixed with cold methanol. Cells were permeabilized with 0.2% Triton X-100. After
blocking with 10% BSA in PBS for 1 h, primary monoclonal COUP-TFII (R&D) and
polyclonal nucleolin (Novus Biologicals) antibodies were added (1:100) for 2 h. The
cells were stained with secondary anti-mouse antibody labeled with DyLight™ 488 or
anti-rabbit antibody labeled with rhodamine (TRITC) (Jackson ImmunoResearch, West
Grove, PA) (1:500).

Cells were incubated with Hoechst (2,5'-Bi-1H-benzimidazole,
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Invitrogen) for 10 min.

Images were captured using an Olympus FV1000 confocal

microscope with a 40x objective lens using FIuo View™ software.

Immunohistochemistry of breast tissue microarrays (TMA)

COUP-TFII and nucleolin immunohistochemistry (IHC) was performed using
commercial breast tissue microarrays BR961 and BR963 (U.S. Biomax) or an in-house
TMA constructed following ethical approval from St. Vincent's University Hospital
Ethics Board with tissue from 332 primary breast patients, following written informed
consent, as previously described [61,244]. Data on the patients included pathological
characteristics (tumor size, grade, lymph node status, estrogen receptor status) as well as
treatment with radiotherapy, chemotherapy or tamoxifen. Follow-up data, median 7.72
years, was collected on the patients to determine disease free and overall survival.
Staining was called by two independent observers using the Allred scoring system [61].
Xenografted MCF7 and HCT116 tumors were used as positive and negative controls,
respectively (data not shown). Anti-Nucleolin antibody (Clone 4E2, Abcam) was diluted
at 1:500 with overnight incubation at 4°C for BR961 and BR963. A metastatic melanoma
was used as a positive control for nucleolin (data not shown). COUP-TFII and nucleolin
staining were expressed as H-score: product of intensity (0 to 3 scale, 0

= no expression,

3 strongest expression) and frequency (fraction positive, 0-100%).

Statistical Evaluation of IHe

The univariate associations between COUP-TFII and nucleolin H-scores and
categorical predictors used the Kruskal-Wallis test [61]. A multiple linear regression
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model was used to fit with COUP-TFII and nucleolin H-scores against pathology, tumor
grade, and TNM, classification. The TNM staging system classifies tumors according to
disease progression based on the tumor size (T), regional lymph node involvement (N),
and distant metastasis (M). Upon assignment of TNM, tumors can further be designated
into a condensed grade/stage (I-IV) based on disease severity [245]. Comparisons in the
ERa-positive invasive ductal carcinoma subset and among TNM classification within
tumor grades were examined (t-test).

Fisher's exact test was used for categorical

variables to compare two proportions. Kaplan Meier estimates of survival functions were
computed and the Wilcoxon test was used to compare survival curves. Two-sided P
values of <0.05 were considered to be statistically significant.

Transient transfection
MCF-7 and T47D cells were transfected with a constant amount of total plasmid
DNA, pcDNA 3.1 (Promega), pCMV-Tag2 (Stratagene), pcDNA 3.1-mCOUP-TFII
(kindly provided by Drs. Sophia and Ming-Jer Tsai [246]), pCMV2-nucleolin [247] using
Fugene 6 or HD (Roche) for 24 h prior to treatment with 10 ~M CRO (negative control),
AS1411, or random oligomer (RO, 5'-GTTCAGCAGTCACGATTCAGTCCAGT-3') for
6 or 24 h, as indicated. Where indicated, cells were co-treated with 1 ~M atRA or 9cRA
for 6 h. Transient transfection of MCF-7 cells with the RARB promoter tk-luciferase
reporter (kindly provided by Dr. Richard M. Niles [248]) and pTK-Renilla (Promega), for
dualluciferase reporter assays, as described [130] .

RNA Isolation, RT-PCR and Quantitative Real-Time-PCR (QRT-PCR)
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RNA was extracted from cells using Trizol (Invitrogen) or RNeasy (Qiagen,
Valencia, CA). The High Capacity cDNA Reverse Transcription kit (Applied
Biosystems) was used to reverse transcribe total RNA. QRT-PCR for RARB2, NCL,

ESR1, ESR2, GAPDH, and 18S, using Taqman primers and probes as Assays-onDemand, was performed in the ABI PRISM 7900 SDS 2.1 (Applied Biosystems,
Carlsbad, CA). COUP-TFII (NR2F2) and RRIGl [249] mRNA expression was measured
by QRT-PCR using the SYBR green method and normalized by GAPDH [116]. Analysis
and fold differences were determined using the comparative CT method. Fold change
was calculated from the ~~CT values with the formula T:lL'.CT and data are relative to
EtOH-treated and control vector transfected cells.

siRNA transfection
For nuc1eolin, cells were transfected for 48 h with 25 nM (MCF-7) or 10 nM
(T47D) nuc1eolin Stealth Select RNAi or Stealth RNAi Negative Control (Invitrogen)
using Lipofectamine RNAiMAX (Invitrogen). For COUP-TFII, MCF-7 cells were
transfected for 48 h with 100 pmol NR2F2 Silencer Select siRNA (Ambion). Following
transfection, cells were treated for 6 h with 1 IlM atRA.

Chromatin immunoprecipitation (ChIP)
MCF-7 cells were transfected with pIRES-COUP-TFII-FLAG or empty vector for
24 hand semm starved for 48 h in medium containing 5% dextran-coated charcoal
stripped FBS (DCC-FBS) (Atlanta Biologicals, Lawrenceville, GA). Cells were treated
with 1 IlM atRA or EtOH for 1 h before crosslinking with 1% formaldehyde for 5 min.
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ChIP was perfonned using MAGnify ChIP (Invitrogen). Lysates were incubated with
anti-FLAG M2 antibody (Sigma) or mouse IgG (Invitrogen). The following primers
were used for PCR to amplify the region of the RARB2 promoter containing a COUPTFII binding site [118]: F 5'-CAGGGCTGCTGGGAGTTTTTA-3' and R 5'GGCATCCCAGTCCTCAAACAGC-3'. Quantitation was performed as described in
[250].

Statistical analysis

Values are reported as ± SEM. Student's t test was used for comparisons between
control and treatment. One way ANOV A was used for multiple comparisons followed by
Student-Newman-Keuls or Dunnett's post-hoc tests using GraphPad Prism. P values
considered statistically significant are indicated.

RESULTS

Identification of COUP-TFII-associated proteins

C-tenninal FLAG-tagged COUP-TFII was overexpressed in MCF-7 cells (-2-fold
higher expression compared to COUP-TFII endogenous expression; Appendix I, Fig. S 1
and S2) and interacting proteins were captured by immunoprecipitation (IP) with antiFLAG-affinity gel (Appendix I, Fig. S2A).

The negative control was MCF-7 cells

transfected with the pIRES-GFP-1a parental vector and parallel purification of
nonspecific interacting proteins (Appendix I, Table S1). The capture of COUP-TFIIFLAG by the anti-FLAG affinity gel was demonstrated (Appendix I, Fig. S2C). Serial
glycine steps eluted COUP-TFII-FLAG-associated proteins (Appendix I, Fig. S3). In the
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first elution, 18 proteins having a 'moderate association' with COUP-TFII including
hsp70, an established NR chaperone that interacts with COUP-TFI [114], were identified
(Appendix I, Table S2). The second elution identified 36 more 'strongly associated'
nuclear proteins, i.e., ribnucleoproteins, histones, DNA repair proteins, and RNA binding
proteins, and nucleolin (Table 2), reflecting COUP-TFII nuclear localization.
Nucleolin is a multifunctional protein with roles in processes including
transcription, ribosome biogenesis, DNA replication, histone chaperone/chromatin
remodeling, apoptosis, and macropinocytosis [251-254]. There are several examples of
nucleolin functioning as a transcription factor or as a coregulator through its interactions
with other proteins [255-257]. Because nucleolin plays multiple nuclear roles and is a
target of anticancer therapy [252], we selected nucleolin for follow-up studies.
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Table 2. Identification of COUP-TFII interacting proteins in MCF -7 cells.
WCE from pCOUP-TFII-FLAG-transfected MCF-7 cells (Fig. 6) was incubated with
anti-FLAG affinity gel, eluted with 0.1 M glycine, pH 3.5 for 5 min. at 95°C, and
subjected to MudPIT peptide identification. Matched (No) indicates the number of
sequenced pep tides that match the full length protein. Coverage indicates the % of the
total protein matched. (Only matches of> 1 peptide match and/or> 3% coverage are
included.)
Protein name
Histones
Histone H1.0
Histone H2A type 2-C
Histone H1.4
Proteins involved in cell cycle &
proliferation
Antigen KI-67
Regulator of chromosome
condensation
Poly [ADP-ribose] polymerase 1
(PARP-1)
Proteins involved in
transcription
Activated RNA polymerase II
transcriptional coactivator p15
DNA Repair Proteins
DNA topoisomerase 1
DNA topoisomerase 2-beta
(Topolll3)
ATP-dependent DNA helicase 2
subunit 1
ATP-dependent DNA helicase 2
subunit 2
Peptidyl-prolyl cis-trans isomerase
B
RNA binding proteins
RNA-binding protein FUS
Splicing factor, arginine/serine-rich
1
Splicing factor, arginine/serine-rich
9
Splicing factor, arginine/serine-rich
7
Other nuclear proteins
Nonhistone chromosomal protein
HMG14
Nucleolin Protein C23
Heat shock cognate 71 kDa protein
GTP-binding nuclear protein Ran

Accession
~GI~

Mass
~Mr~

pi

Matched
~No~

Coverage
~%~

P07305
Q16777
P10412

20719
5919
21721

11.2
11.8
11.4

1
1
7

6.7
16.1
4.1

P46013

358525

9.8

6

0.5

P18754

44941

7.7

4

3.1

P09874

112881

9.2

7

5.7

P53999

14255

9.9

P11387

90669

9.6

5

1.6

Q02880

183152

8.4

4

2.0

P12956

69668

6.6

3

2.1

P13010

82521

5.7

3

3.0

P23284

22728

9.6

3

10.6

P35637

53394

9.5

3

2.7

Q07955

27597

10.5

4

12.6

Q13242

25526

8.9

2

5.4

Q16629

27350

11.8

2

3.8

P051 14

10522

10.0

2

24.2

P19338
P11142
P62826

76167
70854
24408

4.6
5.4
7.6

3
2
2

1.7
4.3
9.7
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8.7

Heat shock 70 kDa protein 1
(hsp70, HSPA 1)

P08107

70009

53

5.6

2

4.4

Endogenous COUP-TFII and nucleolin interact in MCF-7 and T47D cells

We next examined endogenous nucleolin-COUP-TFII interaction in untreated
MCF-7 cells. IP with a COUP-TFII antibody detected nucleolin interaction in the NE
(Fig. 6A), although nucleolin is in CE as well (Appendix I, Fig. S4A). We did not detect
COUP-TFII-nucleolin interaction in CE because COUP-TFII is not in the CE (Appendix
I, Fig S4A).

Reciprocal co-IP of COUP-TFII with nuclear nucleolin was detected

(Appendix I, Fig. S4A). Another example of a COUP-TFII- nucleolin co-IP in MCF-7
cells is also provided (Appendix I, Fig. S4C and D). To examine whether COUP-TFII
interacts with nucleolin in another luminal breast cancer cell line, we performed IP with a
COUP-TFII antibody in T47D cells and confirmed nucleolin-COUP-TFII interaction in
the NE (Fig 6B). Immunofluorescence microscopy revealed a pattern of co-localization
of endogenous nucleolin and COUP-TFII in the nucleus, but not within the nucleolus nor
in the cytoplasm, of MCF-7 cells (Fig. 6C). These data confirm endogenous COUPTFII-nucleolin nuclear interaction.

Because the focus of this study is COUP-TFII-

interacting proteins, we did not evaluate COUP-TFI-nucleolin interaction.
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Figure 6. Endogenous nuclear nucleolin-COUP-TFll interaction in MCF-7 and
T47D cells.
NE (200 ~g protein) from MCF-7 cells (A) and (400 ~g protein) from T47D (B) cells
were immunoprecipitated with COUP-TFII antibody or with rabbit IgG (negative
control), followed by western blot analysis for nucleolin and COUP-TFII. 5% input NE
serves as loading control. C, Immunofluorescent staining of endogenous COUP-TFII
(green) and nucleolin (red) in the nuclei (Hoechst, blue) ofMCF-7 cells. Merged images
are shown at the right. Bar is 10 ~m. D, schematic representation of the N- terminal
maltose binding protein (MBP)-tagged recombinant nucleolin proteins used for MBP
pull-down assays. MBP was fused to the N-termini of the RNA binding domains (RED)
and/or the arginine/glycine-rich domain (RGG) of nucleolin. E, In vitro
transcribed/translated COUP-TFII was incubated with the MBP-nucleolin fragments or
MBP. Interacting proteins were captured with amylose resin. Eluted proteins were
probed for COUP-TFII (top) and MBP (bottom, control).
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Direct interaction of CO UP- TFII with the RGG domain of nucleolin

To determine if COUP-TFII interacts directly with nucleolin and which domain(s)
are involved, in vitro transcribed/translated COUP-TFII and MBP-tagged recombinant
nucleolin polypeptides were incubated with an amylose affinity resin (Fig. 6D and E).
The MBP fusion proteins contain the RNA binding domains (RBDl ,2,3,4) and/or the
arginine-glycine repeat (RGG). Nine RGG repeats are present in the C-terminus of
nucleolin.

Only these domains were investigated because the N-terminal domain of

nucleolin cannot be expressed in E. coli [247]. COUP-TFII was bound to all MBPtagged polypeptides containing the RGG domain but not with MBP-RBDl,2, MBPRBD3,4, or MBP alone. RGG9 appears to interact with COUP-TFII with weaker affinity
compared to RGG4, perhaps because of the lower abundance of the MBP-RGG9 protein
relative to MBP-RGG4. Overall, these results indicate that the C-terminal RGG domain
is the minimal domain required for COUP-TFII-nucleolin interaction.

Immunohistochemical COUP-TFII and nucleolin staining in human breast tissue and
tumor tissue microarrays

Nuclear COUP-TFII and nucleolin immunoreactivity were examined in two
independent human breast tissue micro arrays (TMAs, Fig. 7). In the TMAs from

u.s.

Biomax, significant differences in COUP-TFII staining were observed between TNM
classes of tumor grades II (d = -51.7, P = 0.078) and II-III (d = -58.5, P = 0.046) (Fig.
7C). COUP-TFII and nucleolin staining were correlated in invasive ductal carcinomas
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(<j>p

= 0.31, p=0.0281;

<j>s

= 0.30, p=0.0334). Normal breast tissue was also positive for

COUP-TFII expression (Average H-score 127.5, SEM 5; data not shown). In a separate
breast TMA [61], staining of a total of 332 patient tumors showed -47% were positive
for nuclear COUP-TFII (Table 3, Fig. 7F). There was a significant association between
tumor grade and COUP-TFII with high grade tumors tending to be COUP-TFII negative
(Table 3). COUP-TFII was also significantly positively associated with ERa, SRC-l,
PEA3, MMP2, and phospho-Src and negatively associated with HER2 (Table 3). High
SRC-l (NCOA1) was associated with a favorable response to TAM [258], a finding that
corresponds to COUP-TFII's role in 4-0HT-medicated inhibition of breast cancer cell
proliferation [116] . However, breast tumors from aromatase inhibitor-resistant patients
show high expression of SRC-l and a reduction in disease-free survival [259]; thus, the
relationship
investigation.

between COUP- TFII

and

SRC-l

expression will

require further

SRC-l and PEA3 synergistically activated COUP-TFII-promoter

luciferase activity in transiently transfected He La cells [181]. PEA3 directly activates
MMP2 transcription [244]; hence COUP-TFII may be correlated with MMP2 through the
PEA3-COUP- TFII connection, although this hypothesis will require further analysis
beyond the scope of the present study.

The relationship between COUP-TFII and

phospho-Src may be because activation of Src is part of the MAPK pathway that
increases COUP-TFII expression [183]. According to Kaplan Meier, COUP-TFII did not
associate with disease free survival in tamoxifen-treated patients (p = 0.447 1, Fig. 7H and
I).
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Figure 7. COUP-TFII and nucleolin in breast cancer tissue microarrays.
A and B, COUP-TFII immunostaining at 200x: A, benign breast tissue (H-score 30) and
B, invasive ductal carcinomas, grade 2 (H-score 153), Bar is 200 mm, C, Average ±
SEM ofH-score for nuclear COUP-TFII staining in ERa-positive invasive ductal
carcinomas by tumor grade. * significantly different from T2NOMO (p < 0.05). D and E,
Nucleolin immunostaining at 400x: D, benign breast tissue (H-score 13) and E, invasive
ductal carcinomas, grade 3 (H-score 151). Bar is 100 J..Lm. F and G, immunohistochemical
localization ofCOUP-TFII (lOO x, inset: 200x) on a tissue micro array constructed from
archival tissue from 332 breast cancer patients [61] showing positively (F) and negatively
(G) stained cores COUP-TFII at 200x, bar is 100 J..Lm. H and I, Kaplan-Meier estimates
of disease-free survival functions were computed, and the Wilcoxon test was used to
compare survival curves, In addition, the Wilcoxon rank sum test was used to compare
two medians. The data are not statistically significant.
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Table 3. COUP-TFII staining in breast tumor microarray.
Associated expression of COUP-TFII with ERa, PR, HER2, SRC-l, AIBl, Pea3, AIBl,
MMP2, and phospho-Src (psrc) staining in 560 human breast tumors [61,244]. Statistical
analysis was performed using the Fisher's exact test, and a P value of <0.05 is considered
to be significant (bold values).

ER
neg
~os

PR
neg
~os

Her2
neg
~os

Grade
1
2
3
Node
neg
~os

Recurrence
neg
~os

SRC-1
neg
~os

AIB1
neg
~os

Pea3
neg
~os

MMP2
neg
~os

psrc
neg

pos

Total
Population
n=321

% COUPTFII
positive
47%

99
222

34.3
52.3

0.004

133
146

50.4
44.5

0.339

267
62

50.2
32.3

0.011

24
122
112

54.2
54.1
33.0

0.003

156
167

47.4
46.1

0.824

200
132

46.0
47.7

0.822

214
113

41 .6
56.6

0.011

88
221

25.0
55.7

<.001

120
120

35.8
58.3

0.001

29
284

20.7
48.2

0.005

226
87

42.0
56.3

0.031

P
value
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atRA enhances COUP-TFII binding to the RARB2 promoter

COUP- TFII is required for atRA- or 9cRA- induced RARB2 expression in breast
cancer cells [118,131] and binds the RARB2 promoter in electrophoretic mobility shift
assays [118]. To examine COUP-TFII interaction with the RARB2 promoter, we first
examined recruitment of endogenous COUP-TFII to the RARB2 promoter using the R&D
systems COUP-TFII antibody, but were unable to detect product in the PCR reactions
(data not shown) likely due to lower COUP-TFII protein in MCF-7 cells compared to
C3HlOT1I2 CH3 mouse embryo mesenchymal cells that express high levels of COUP-

TFII [260]. To obviate this difficulty, MCF-7 cells were transfected with an empty
vector or COUP-TFII-FLAG and ChIP was performed after FLAG IP. ChIP revealed for
the first time that COUP- TFII binds the RARB2 promoter and atRA increased COUP-

TFII occupancy at the RARB2 promoter by 72% in MCF-7 cells (Fig. 8A; Appendix I,
Fig. S5).

AS1411 inhibits COUP-TFII-stimulated RARB2 gene expression in MCF-7 and T47D
breast cancer cells

Once establishing the presence of COUP- TFII at the promoter of its target gene
RARB2, we sought to determine if nucleolin functions as a coactivator for COUP-TFII-

mediated RARB2 expression. RARB2 was increased in MCF-7 cells transfected with
COUP- TFII and nucleolin overexpression potentiated the RARB2 induction in a
concentration-dependent manner (Fig. 8B).

Further, because the G-rich, G-quartet

forming DNA aptamer AS 1411 binds and reduces nucleolin activity [252,261], we
hypothesized that AS1411 would inhibit COUP-TFII-stimulated RARB2 expression.
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AS1411 inhibited the COUP-TFII-induced increase in RARB2, while CRO (negative
control) had no effect (Fig. SC).

Although nucleolin did not affect basal RARB2

expression, nucleolin abrogated the inhibition of RARB2 transcription by AS1411 (Fig.
SC). COUP-TFII also increased luciferase activity from a RARB gene promoter-reporter
and AS 1411 abrogated luciferase induction (Fig. SD).
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Figure 8. COUP-TFII increases RARP2 transcription in MCF -7 cells.
A, ChIP of COUP-TFIl-FLAG to the RARB2 promoter in MCF-7 cells transfected with
empty vector (EV) or COUP-TFIl (CIl) and treated with EtOH or 1 /lM atRA for 6 h. *
P < 0.05 versus E control, f P < 0.05 versus CIl-EtOH. B-C, Cells were transfected with
parental or expression plasmids for COUP-TFIl or nucleolin for 24 h and were treated
with EtOH, 10 /lM CRO or AS1411 for 24 h post-transfection. For C, cells were
transfected with 0.5 /lg and 1 /lg of nucleolin and COUP-TFIl expression vector,
respectively. QRT-PCR was performed to determine RARB2 expression. Values are the
average of 6 separate experiments ± SEM. D, Cells were transfected with pcDNA or
pcCOUP-TFIl and treated with 10 /lM RO or AS1411 for 24 h. Dualluciferase activity
was expressed relative to the pcDNA-transfected, no-treatment control. Values are mean
± S.E.M. of two separate experiments. For B-D, * P < 0.05 versus vector control, **
COUP-TFIl alone, or ... between the indicated values.
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To be sure that any effect of AS1411 on RARB2 is not cell-line specific, MCF-7
and T47D cells with similar nucleolin expression (Appendix I, Fig. S6) were tested.
T47D has -40% lower COUP-TFII than MCF-7 (Appendix I, Fig. S6). Both atRA and
9cRA increased RARB2 expression in MCF-7 and T47D cells, with greater induction in
T47D, and increased NR2F2 (COUP-TFII) expression in T47D (Fig. 9A-B).
Pretreatment of MCF-7 cells with AS1411, but not negative control CRO,
reduced atRA-induced RARB2 expression (Fig. 9C). Transfection of MCF-7 cells with a
nucleolin expression vector increased basal RARB2 except in AS1411-treated cells.
Nucleolin and atRA additively increased RARB2 expression in MCF-7 cells and AS1411,
but not CRO, reduced RARB2 induction. Nucleolin significantly abrogated the inhibition
of RARB2 expression by AS1411.

COUP-TFII mRNA levels were not significantly

reduced by AS1411 (Appendix I, Fig. S7). Neither ER antagonists ICI 182,780 nor 4ORT blocked atRA-induced RARB2 expression, indicating that ER is not involved in
COUP-TFII-activated RARB2 expression (Fig. 9C).

ICI and 4-0RT increased basal

RARB2 in MCF-7, in agreement with RARB-Iuciferase reporter activation in transfected

MCF-7 cells [262].
Pretreatment of T47D cells with AS1411, but not CRO, reduced atRA-induced
RARB2 expression and co-transfection with an expression vector for nucleolin

significantly abrogated the inhibition of RARB2 expression by AS1411 (Fig. 9D).
AS1411 had no effect on MCF-7 cell viability for the treatment times used in these
experiments (Appendix I, Fig. S8), commensurate with previous findings that MCF-7
viability is inhibited only after 6 d of AS1411 treatment [261].
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RARB2 expression is inhibited by nucleolin or COUP-TFII knockdown

siNucleolin reduced nucleolin (NCL) mRNA by 37-58% and protein by 22-35%
(Fig. lOA) in MCF-7 cells. In parallel, basal RARB2 was reduced 32-56% (Fig. lOA).
To determine if nucleolin knockdown inhibited atRA-induced RARB2, T47D cells were
transfected with siNucleolin and untreated or treated with atRA (Fig. lOB). atRA had no
effect on nucleolin knockdown (Fig. lOB). Analogous to the MCF-7 cells, siNucleolin
reduced RARB2 rnRNA (Fig. lOB). siNucleolin inhibited the atRA induction of RARB2
-36%. Taken together, results from AS1411 and siNucleolin studies indicate a functional
role for nucleolin as a coactivator of COUP-TFII-regulated atRA-induced RARB2
expression in T47D and MCF-7 cells.
siCOUP-TFII

reduced

COUP-TFII

transcription and protein (Fig. 10C).

RAR~2

protein

and,

consequently,

RARB2

stimulates retinoic acid receptor-induced

gene 1 (RRIG1) transcription [263] . siCOUP-TFII reduced basal and atRA-induced
RRIGl expreSSIOn.

Transfection with COUP-TFII increased RRIG1.

These data

substantiate COUP-TFII' s regulation of functional RAR~2.

Effects of AS1411 on nucleolin-COUP-TFII nuclear interaction

AS 1411 reduced the nuclear/cytoplasmic ratio of the nucleolin-interacting protein
PRMT5 (Protein Arginine Methyltransferase 5) in DU145 prostate cancer cells [247].
AS1411 or CRO did not change nuclear COUP-TFII or nucleolin or cytosolic nucleolin
in MCF-7 cells (Fig. llA-B). There was no change in relative COUP-TFII-nucleolin
interaction in MCF-7 cells treated with AS 1411 (Fig. 11 C- D).
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Figure 10. Reduction of COUP-TFII or nucleolin decreases
MCF-7 cells.

RAR~2

transcription in

MCF-7 (A) and T47D (B) cells were transfected with control siRNA or an siRNA
targeting nucleolin for 48 h. T47D cells were treated with EtOH or 1 flM atRA for 24 h.
QRT-PCR for nucleolin (NCL) and RARB2. Values are the average of triplicates. C,
Western blot showing COUP-TFIl and RAR~2 expression after transfection with
siCOUP-TFlI. Values are relative to ~-actin . MCF-7 were transfected with siControl or
siCOUP-TFII for 48 h and treated with 1 flM atRA for 6 h. QRT-PCR was also
performed for RRIGI. P < 0.001 * versus control or ** versus atRA.
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COUP-TFII , then stripped and reprobed for HDAC1 and a-tubulin. B, Relative
nucleolin and COUP-TFII expression (normalized to respective loading controls and
lmtreated sample protein ratios were set to 1 for NE and CE). Bars are the mean ± SEM
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control: COUP-TFII antibody incubated with beads and buffer without NE. D, The ratio
of nuclear nucleolinfCOUP-TFII is the mean ± SEM of 3 experiments.
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DISCUSSION

COUP-TFII plays an undefined role in breast cancer [116]. In this report, we
identify nucleolin as a new functional partner for COUP-TFII. We have demonstrated for
the first time that COUP- TFII binds nucleolin in vitro and in vivo. In breast tumors,
nuclear nucleolin correlates with ERa and cell proliferation [264,265].

Here

mc

staining revealed a correlation between nuclear COUP- TFII and nucleolin staining in
invasive ductal carcinoma, a finding that reflects a previous report showing
overexpression of COUP- TFII in A549 lung adenocarcinoma cells increased in vitro
tumorigenicity and migration [211]. We demonstrate that nucleolin acts as a coactivator
of endogenous COUP- TFII transcriptional activity for RARB2 in breast cancer cells.
Similarly, nucleolin acted as a coregulator by interacting with c-Jun and Spi and
increasing cytosolic phospholipase A2 (cPLA2) gene transcription [256].
We report a positive correlation between COUP-TFII and ERa, SRC-I, Pea3,
MMP2, and phospho-Src expression, an inverse correlation of COUP- TFII with tumor
grade and reduced COUP-TFII in ERa-positive, invasive ductal carcinomas with
increased TNM stage within tumor grades II and III and HER2 positivity. These data are
in agreement with Oncomine analysis demonstrating NR2F2 is higher in ERa+ tumors
and lower in metastatic breast tumors in microarray data [266] (Appendix I, Fig. S9).
These observations indicate that COUP TFII may playa role in "phenotype maintenance"
and that its ftffiction may be restricted to the luminal breast cancer subtypes.

We

speculate that the precise role of COUP- TFII in breast cancer depends on cellular context,
which is consistent with the role of other nuclear receptors in breast cancer [267], and
remains to be fully elucidated.
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Other COUP-TFII-interacting proteins identified here include PARP-l, which
also interacts with nucleolin [268], TOPOIIP, involved in transcriptional activation by
NRs [269,270], and DNA topoisomerase I (Topol), which localizes to active transcription
sites [271]. Reflecting its NR chaperone role and interaction with COUP-TFI [114],
Hsp70 interacted with COUP-TFII.

Other COUP-TFII-interacting proteins including

hnRNP A2/B1, RPS20, RPL15, and RPL21 were also identified as binding with
nucleolin to a c-myc G-quadmplex affinity column [272].
Nucleolin is a key target of the anticancer aptamer AS 1411, although AS 1411
interacts with other proteins, e.g. , NEMO to inhibit NFKB activation and PARP-1 [252].
AS1411 has pleiotropic effects on nucleolin, e.g., inhibiting nucleolin binding to the AUrich element in the 3' UTR of BeL2 in MCF-7 cells causing apoptosis [273] and
stimulating macropinocytosis [251]. AS1411 is used to functionally inhibit nucleolin
[274]. Here, AS1411 and siNucleolin reduced COUP-TFII-induced RARB2 expression in
MCF-7 and T47D cells and cotransfection with nucleolin reduced AS 1411-inhibition.
AS1411 did not alter nuclear COUP-TFII-nucleolin interaction, indicating that the
mechanism for AS 141.1 inhibition of RARB2 expression is independent of reducing
nuclear COUP-TFII protein, a result different from AS1411 reducing nuclear PRMT5 in
DU145 cells [247].

The inhibition of atRA- and COUP-TFII- regulated RARB2

expression by AS 1411 may also be independent of its effect on nucleolin and may
indicate a potential adverse 'side effect' of AS1411 that may be a concern if this dmg is
used for breast cancer therapy.
In conclusion, COUP-TFII interacting proteins were identified in MCF-7 breast

cancer cells. Endogenous COUP-TFII and nucleolin interact in both MCF-7 and T47D
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luminal breast cancer cells. A coregulatory role for nucleolin in COUP-TFII-mediated
RARB2 transcription was described (Fig. 12). Retinoids, e.g. 9cRA and atRA, and

RAR~

have long been associated with tumor suppressive properties such as reduced cell
proliferation, inflammation, and solid tumor formation, as well as enhanced apoptosis
(reviewed in [275]).
RAR~2

RAR~2

expression is reduced in breast tumors and restoration of

expression increases sensitivity to tumor growth inhibition by retinoids [276].

Ours is the first demonstration that atRA increased COUP-TFII-RAR,82 promoter
interaction by ChIP. Since serum carotenoids levels are inversely associated with breast
cancer risk in women with high mammographic density [277], the increase in RARB2 in
response to COUP-TFII-nucleolin interaction is consistent with a role for COUP- TFII in
phenotype maintenance. In agreement with a previous report [118], we observed a much
higher induction of RARB2 in T47D in response to atRA compared to MCF-7 despite, as
newly reported here, lower COUP-TFII expression.

These data indicate that other

mechanisms are also involved. COUP-TFII protein staining in TMAs correlates with
ERa expression and an inverse correlation of COUP- TFII with tumor grade in ERapositive, invasive ductal carcinomas was detected, a finding that correlates with reduced
COUP-TFII expression in endocrine-resistant breast cancer cells [116]. Together, these
data suggest that COUP-TFII may be important in differentiated ERa-expressing,
retinoid-responsive, epithelial breast cancer cells and that reduced COUP- TFII leads to
tumor advancement, including endocrine resistance.
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atRA

AS1411

Figure 12. Model of nucleolin-COUP-TFII interaction and upregulation of RARB2
expression.
COUP-TFII binds its response elements as either a homodimer or as a heterodimer with
RXR [107] . Previous reports demonstrated that 1) 9cisRA and atRA bind COUP-TFII
and increase COUP-TFII transcriptional activity [120] ; 2) Nucleolin acts as a
transcriptional coregulator by interacting with cJun and Spl [256]; 3) COUP-TFI and
COUP-TFII increase RARB2 expression in cooperation with RARa and CBP [118]. Here
we demonstrated that 1) nucleolin interacts directly with nuclear COUP-TFII; 2) atRA
and 9-cisRA increased RARB2 rnRNA; 3) AS1411 , used as a functional inhibitor of
nucleolin [252,274], inhibited COUP-TFII-upregulation of RARB2 gene transcription; 4)
siRNA knockdown of nucleolin reduces induction of RARB2 and reduced RAR~2
protein.
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CHAPTER IV - COUP-TFII INIDBITS NFlCB ACTIVATION IN BREAST
CANCER CELLS AND RESTORES ENDOCRINE SENSITIVITY

INTRODUCTION

Selective estrogen receptor modulators (SERMs) such as tamoxifen (TAM) exert
antiproliferative effects on breast cancer by competing with estrogens for binding to
estrogen receptor a (ERa), leading to an inhibition of downstream genes, including those
involved in breast cancer proliferation. Fulvestrant is a selective ERa downregulator
(SERD) because it causes proteasomal degradation of ERa in addition to its SERM-like
ability to antagonize estrogen-activated ERa transactivation [278]. T AM inhibits cell
cycle progression and induces apoptosis [45,46]. TAM has greatly increased the survival
rate of breast cancer patients since its initial FDA approval in 1977, resulting in a 31 %
reduction in annual death rate [48,279].

Despite the initial efficacy of SERM and

aromatase inhibitor treatment, approximately 40% of patients relapse and die from
metastatic disease because the cancer cells become refractory to endocrine therapies [56].
The mechanisms for acquired endocrine resistance are complex and a better
tmderstanding of maintenance of endocrine sensitivity is clearly needed.

Reduced

expression of the orphan nuclear receptor chicken ovalbumin upstream promoter
transcription factor II (COUP-TFII) has a demonstrated role in acquired endocrine
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resistance

In

a breast cancer cell line model of human disease progression [116] .

Restoration of COUP-TFII expression, which is reduced in endocrine-resistant breast
cancer cell lines, inhibited cell proliferation and motility and increased apoptosis in TAM
and fulvestrant-treated endocrine-resistant LCC9 and LY2 breast cancer cells [116].
Conversely, inhibition of COUP-TFII expression caused MCF-7 cells to become resistant
to SERM and fulvestrant inhibition of proliferation [116].

A mechanism for the

involvement of COUP-TFII in maintenance of endocrine sensitivity has not yet been
determined. Since COUP-TFII acts as either a transcriptional activator or repressor in a
gene- and cell-specific manner [226] , the mechanism of action may involve modulation
of specific target genes including tumor suppressors and oncogenes.
The NFKB family of dimeric transcription factors has important functions related
to immune and inflammatory responses, and recent studies have demonstrated NFKB
activation plays a role in acquired endocrine-resistant breast cancer [87,88,280]. Inactive
NFKB is located in the cytoplasm bound to IKB , the inhibitor of NFKB. Also present in
the cytoplasm is the IKK complex containing the regulatory subunit NEMO (nuclear
factor-KB essential modulator or IKKy) and the catalytic subunits IKKa and

IKK~.

Upon

activation by a variety of stimuli, the IKK complex phosphorylates the inhibitor IKB
leading to its degradation, freeing the now activated NFKB to trans locate to the nucleus to
regulate target gene transcription.

Because NFKB activation results in expression of

genes that lead to anti-apoptotic and pro-proliferative activities, increased NFKB
signaling promotes cancer cell survival [281].
Dysregulation of the NFKB subunits p65 (RELA) , RelB (RELB) , pSO (NFKB1),
pS2 (NFKB2) , and c-Rel (REL) results in altered activation of the NFKB pathway in
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breast cancer. Increased expression of pSOINFKBl, pS21NFKB2, and c-Rel was detected
in breast tumors compared to adjacent normal tissue [282]. Elevated pSO/NFKBl-DNA
binding correlated with metastatic relapse and reduced disease-free survival in patients
with ERa-positive tumors [283]. An increase in NFKB activity has been reported in
endocrine-resistant breast cancer cells [87,280,284]. The amount of RelAlp6S protein
was also elevated [87].

The expression and DNA binding of pSO and p6S are also

enhanced in LCCl estrogen-independent, TAM-sensitive breast cancer cells compared to
MCF-7 estrogen-dependent cells, further demonstrating a role for NFKB in the pathway
to endocrine resistance [93].
Since COUP-TFII expression is decreased in endocrine-resistant breast cancer
cells, we hypothesized COUP-TFII may playa part in the normal suppression of NFKB
activity in endocrine-sensitive breast cancer cells by regulating the transcription of
components of the NFKB pathway.

In this study, we observed that COUP-TFII

overexpression inhibited NFKB activity in LCC9 endocrine-resistant breast cancer cells.
This suppression of the NFKB pathway resulted in reduced expression of downstream
NFKB target genes as well as NFKB subunits and increased sensitivity to 4hydroxytamoxifen (4-0HT) treatment.

Our results provide a mechanism by which

COUP-TFII maintains endocrine sensitivity by suppressing NFKB expression and activity
in breast cancer cells.

MATERIALS AND METHODS

Chemicals
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4-hydroxytamoxifen (4-0HT) and BMS-345541 were purchased from SigmaAldrich (St. Louis, MO).

Tumor necrosis factor a (TNFa) was purchased from

PeproTech (Rocky Hill, NJ).

Antibodies

The following antibodies were purchased: monoclonal (mAb) anti-human COUPTFII (R&D systems, Minneapolis, MN); polyclonal RelAlp65, polyclonal and mAb
RelB, and mAb NFKB 1 p105/p50 (Santa Cruz Biotechnology, Santa Cruz, CA);
polyclonal c-Rel, polyclonal NFKBI p105/p50, and polyclonal NFKB2 p100/p52 (Cell
Signaling, Danvers, MA),

~-actin

(Sigma-Aldrich).

HRP- conjugated secondary

antibodies were from GE Healthcare (Piscataway, NJ).

Cell culture and transient transfection

MCF-7 cells were purchased from ATCC and used at passage < 10. LCC9 cells
were kindly provided by Dr. Robert Clarke [285].
maintained as in [116].

MCF-7 and LCC9 cells were

Cells were transiently transfected as indicated in figure legends

using FuGENE HD (Roche, Indianapolis, IN) as per the manufacturer's protocol.

Luciferase assay

To analyze NFKB activity, MCF-7 and LCC9 cells were transiently transfected
with pGL4.32[luc2PINF-KB-RE/Hygro] (Promega, Madison,

Wn containing five copies

of a NFKB response element, pGL4-hRluc-TK (Renilla, Promega), and pcDNA3 .1 or
pcDNA3.1 -mCOUP-TFII (kindly provided by Drs. Sophia and Ming-Jer Tsai [246]) for
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48 h before performing dual luciferase assay (Promega). Where indicated, cotransfection
was performed with plasmids for CBP (kindly provided by Dr. Margarita HadzopoulouCladaras [286]), SRC-l (kindly provided by Dr. Bert W. O'Malley [287]), GRIPlISRC2, or ACTRlSRC-3 (kindly provided by Dr. Michael Stallcup [288]).

NF KB pathway peR array

LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-mCOUP-TFII for 24
h before treating with 10 ng/ml TNFa for 6 h. RNA was isolated using RNeasy (Qiagen,
Valencia,

CA)

and

cDNA

was

prepared

usmg

RT2

First

Strand

Kit

(SABiosciences/Qiagen, Valencia, CA). Human NFKB Signaling Pathway PCR Array
(SABiosciences/Qiagen) was run according to manufacturer's instructions.

Electrophoretic mobility shift assay (EMSA)

MCF-7 and LCC9 cells were transfected with pcDNA3. 1 or pcDNA3.1-mCOUPTFII for 48 h followed by treatment with 10 ng/ml TNFa for 6 h.

Following

centrifugation, cells were resuspended in 10 mM HEPES, 1.5 mM MgClz, 10 mM KCl, 1
mM dithiothreitol (DTT, Sigma-Aldrich), IX protease and phosphatase inhibitors

(Roche).

The cells were lysed with a 27 gauge syringe and centrifuged to obtain

cytosolic extract. The resulting nuclear pellet was resuspended in EMSA buffer (10 mM
Tris HCI, 150 mM KCI, 0.5 mM EDTA, 0.1% Triton-X 100, 12.5% glycerol, pH 7.9
(Sigma-Aldrich), 1 mM DTT, IX protease and phosphatase inhibitor (Roche)) and
sonicated to prepare nuclear extract (NE).
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NFKB sense (S'-AGT TGA GGG GAC TTT CCC AGG C-3') and antisense (S'GCC TGG GAA AGT CCC CTC AAC T-3 ' ) oligonucleotides (Integrated DNA
Technologies, Coralville, IA) were annealed and labeled with

ep]-yATP (PerkinElmer,
2

Waltham, MA) using T4 polynucleotide kinase (Promega) to prepare labeled DNA probe.
The

ep]NFKB
2

response element (RE) probe was purified using the QIAquick

Nucleotide Removal Kit (Qiagen).
25 ug NE from the indicated cells was incubated with poly-dldC (Sigma-Aldrich),

ep]NFKB-RE (labeled probe), and EMSA buffer for 1 h before separating on a 4% non2

denaturing polyacrylamide gel (Bio-Rad, Hercules, CA). For in vitro binding assay, in

vitro transcribed/translated COUP-TFII was prepared as described in [l1S] and incubated
in increasing concentrations with NE from LCC9 cells treated with 10 ng/ml TNFa for 6
h.

NF T<iJ family transcriptional assay
MCF-7 or LCC9 cells were transfected with pcDNA3.1 or pcDNA3. 1-COUPTFII for 48 h and treated with 10 ng/ml TNFa for 6 h before preparing NE. 15 /-lg NE
was used for TransAM NFKB assays (Active Motif, Carlsbad, CA) according to the
manufacturer's protocol. Briefly, NE was added to 8 well strips containing immobilized
NFKB RE oligonucleotide. Primary antibodies specific for NFKB subunits RelB, ReIA,
pSO, pS2, and c-Rel were used to identify subunit-specific NFKB activation. Secondary

HRP-conjugated antibody and provided buffers provided colorimetric quantitation via
spectrophotometric analysis at 450 nm.
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Coimmunoprecipitation

Nuclear extracts were prepared from MCF-7 cells as in [U5]. Dynabeads protein
A (Life Technologies, Carlsbad, CA) were incubated with COUP-TFII antibody (Abcam,
Cambridge, MA) or negative control IgG (Santa Cruz) for 30 minutes prior to the
addition of 400 /J.g MCF-7 NE for 4 h at 4 °c with rotation. Following washes, protein
was eluted with Elution Buffer (Life Technologies, Carlsbad, CA) and pH was adjusted
with 1M TrisHCl.

Cell proliferation assay

MCF-7 and LCC9 cells were grown for 48 h in medium containing 5% charcoalstripped fetal bovine serum (CSS) and transfected with pcDNA or pcDNA-mCOUP-TFII
for 24 h before treatment with 1 /J.M 4-0HT, 10 nglml TNFa, and 0.01-5

!J.M BMS-

345541 in DMSO for 5 days. Cell proliferation was assayed using CellTiter AQueous
One Solution Cell Proliferation Assay (MTS; Promega).

RNA Isolation, RT-PCR and Quantitative Real-Time-PCR (QRT-PCR)

RNA isolation, RT-PCR, and QRT-PCR were performed as

ill

[U5] .

The

following SYBR green primers were used for QRT-PCR analysis, relative to GAPDH
control: RELB [289], REL, NFKBl and NFKB2 [290], IL6 [291], A20fl'NFAlP3 [292],
ICAMl

[293], CCL2 [294], NR2F2 and GAPDH [183], Nr2j2 (Forward 5'-

CCCCCATAGATATGGCAATGGTAGTCAGCACG-3',

Reverse

5'-

TTGATTTATTTATTGAATTGCCATATATGGCC-3'). p65/RELA was measured using
TaqMan Gene Expression Assay (Applied Biosystems) relative to 18S control.
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Microarray analysis

Published micro array data was obtained from Gene Expression Omnibus (GEO)
(dataset GSEI770S) consisting of 298 ERa+ patients treated with tamoxifen for S years
and analyzed to assess the correlation between COUP-TFII (NR2F2) expression and
NFKB subunit (NFKB1, NFKB2, REL, RELA, RELB) and target gene (lCAM1, 1L6,
CCL2, TNFAIP3) expression. Gene expression data was log2 transformed and quantile

normalized prior to analysis. Correlation analysis was performed using the Spearman
Rho (pS) statistic to assess whether NR2F2 expression was inversely correlated with
NFKB subunit/target genes.

Statistical analysis

Statistical analyses were performed as in Chapter III [lIS].

RESULTS

COUP-TFII suppresses NF!d3 activity

To determine if NFKB activity is differentially regulated by COUP-TFII in
endocrine-sensitive versus -resistant cells, MCF-7 (sensitive) and LCC9 (resistant) cells
were transfected with a luciferase reporter containing five tandem repeats of a NFKB
responsive element as well as pcDNA3.1 parental plasmid or pcDNA3.1-COUP-TFII
(Fig. 13A). Basal NFKB activity in LCC9 is -S fold higher than MCF-7 cells. When
treated with TNFa, a dramatic induction of NFKB activity is observed in LCC9 but not
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MCF-7 cells. A statistically significant, dose-dependent decrease in the TNFa-induced
NFKB activation occurs in LCC9 cells upon transfection with increasing amounts of
COUP-TFII.

These data demonstrate that COUP- TFII suppresses NFKB activity in

endocrine-resistant breast cancer cells. The expression of NFKB subunits NFKB2, REL,
and RELB was higher in LCC9 compared to MCF-7 cells (Fig. 13B), accounting for the
higher NFKB activity in LCC9 cells.
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Figure 13. COUP-TFII suppresses NFlCB activity in LCC9 cells.
(A) MCF-7 and LCC9 cells were transfected with a NFKB luciferase reporter and
increasing concentrations of pcDNA3. 1 or pcDNA3.1-COUP-TFII for 48 h and treated
with 10 ng/ml TNFu for 6 h before performing dualluciferase assay (Promega). Firefly
luciferase values are shown relative to protein concentration for a representative
experiment of quadruplicate values ± SEM. * Significantly different P<O.05 from
pcDNA+TNFu in LCC9. (B) Comparison of NFKB subunit mRNA expression in MCF-7
versus LCC9 cells. Values are the mean of 4-8 separate experiments ± SEM. *: P<O.05
versus MCF-7.
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Identification ofCOUP-TFII effect on NFKB pathway
An NF1d3 pathway PCR array was used to determine the effect of COUP-TFII on

the NF1d3 pathway in LCC9 endocrine-resistant cells treated with TNFa using a 3-fold
cutoff (Fig. 14A). As displayed in the resulting heatmap, a general decrease in the
expression of NF1d3 pathway genes was detected upon COUP-TFII overexpression (Fig.
14B).

Many genes suppressed by COUP-TFII greater than 3-fold were NF1d3 -

responsive genes, e.g., CCL2, IL6, LTA, ICAMI, and TNFAIP3, as well as NF1d3 subunits
(RELB) , reflecting a role for COUP-TFII in downregulation of the NF1d3 pathway.

These genes were selected for further analysis.

COUP-TFII suppresses NFKB target gene expression

To extend and confirm the results from the NF1d3 pathway PCR array, MCF-7
and LCC9 cells were transfected with pcDNA3.1 or pcDNA3. 1-COUP-TFII and treated
with TNFa to determine the effect of COUP-TFII on endogenous NF1d3 target gene
expression.

COUP-TFII expression following transient transfection was verified via

western blot (Appendix I, Fig. S 10). Four NF1d3 target genes with known roles in breast
cancer progression were examined through QRT-PCR to validate the results from the
NF1d3 pathway PCR array: interleukin 6 (IL6), intercellular adhesion molecule 1
(ICAMl), TNFa-induced protein 3 (A2D, TNFAIP3), and chemokine (C-C motif) ligand
2 (CCL2) (Fig. 15). TNFa increased the expression of IL6, ICAM1, TNFAIP3, and
CCL2 in both MCF-7 and LCC9 cells (Fig 15A-D). COUP-TFII overexpression reduced

the basal expression of IL6 and CCL2 in LCC9 cells (Fig. 15A and D) and ICAM1 and
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TNFAIP3 in both MCF-7 and LCC9 cells (Fig. 15B and C). The TNFa-induction of IL6

and ICAMI was reduced by COUP-TFIl in LCC9 cells (Fig. 15A and B), while the
TNFa-induction of TNFAIP3 and CCL2 was reduced in MCF-7 cells (Fig. 15C and D).
The suppression of IL6, ICAMl, TNFAIP3, and CCL2 expression by COUP-TFII is in
agreement with the data from the NFKB PCR array.
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Figure 14. COUP-TFII inhibits expression of multiple genes in the NFKB pathway.
LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for 24 h and
treated with 10 ng/ml TNFa for 6 h before preparing RNA and cDNA. (A)
SABiosciences NFKB Pathway Array was used to identify genes with expression altered
greater than 3-fold by addition of COUP-TFII. (B) Heat map displaying fold change of
individual genes in the array.
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Figure 15. COUP-TFII inhibits expression of NFKB target genes.
MCF-7 and LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for
48 h and treated with 10 ng/ml TNFa for 6 h before preparing RNA and cDNA. mRNA
expression of NFKB target genes identified in the NFKB pathway array (A. IL6, B.
ICAM], C. TNFAIP3, D. CCL2) was analyzed by QRT-PCR. Note that relative
expression of each gene was normalized to pcDNA-transfected, control treated cells
within each cell line. Values are the mean of 2-7 separate experiments ± SEM. Bars
indicate p<O.05 between the indicated samples to indicate effect of COUP-TFII on basal
or TNFa-induced gene expression in each cell line.
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COUP-TFII suppresses NF!d3 subunit gene expression
RELB expression was decreased by COUP-TFII overexpression in the NFKB

pathway PCR array. Increased NFKB subunit expression has been reported in several
lineages of endocrine-resistant breast cancer cells [87,88,91], but correlation with COUPTFII expression has not yet been examined. Consistent with these reports, we observed
higher NFKB2, REL, and RELB expression in LCC9 versus MCF-7 cells (Fig. 13B).
TNFa increased the expression of NFKB1, NFKB2, REL, and RELB, but not RELA in
both MCF-7 and LCC9 cells (Fig. 16A-E). COUP-TFII overexpression inhibited the
basal expression of REL and RELA in LCC9 cells (Fig. 16C and E). The TNFa-induction
of NFKB1, REL, and RELB was significantly reduced by COUP-TFII in LCC9 cells (Fig.
16A, C, and D).

At the protein level, COUP-TFII overexpression decreased basal

NFKB1 p105, NFKB2 plOO, and RelB in MCF-7 cells and NFKB2 plOO in LCC9 cells
(Fig. 17). COUP-TFII inhibited the TNFa-induced expression of NFKB2 plOO, ReIA,
RelB, and c-Rel in MCF-7 cells and NFKB1 p105, RelA, and RelB in LCC9 cells (Fig.
17). Thus, COUP-TFII inhibits TNFa-induced increases in NFKB 1 and RelB at both the
mRNA and protein levels in LCC9. Differences between protein and mRNA results for
NFKB subunit expression may have been due to the treatment conditions used for the
experiment, as NFKB mRNA and protein levels may be altered at different timepoints.
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Figure 16. COUP-TFII inhibits mRNA expression ofNFKB subunits in LCC9 cells.
MCF-7 and LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for
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effect of COUP-TFII on basal or TNFa-induced gene expression in each cell line.
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Figure 17. COUP-TFII inhibits protein expression ofNFKB subunits.
MCF-7 and LCC9 cells were transfected with pcDNA3 .1 or pcDNA3.1-COUP-TFII for
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I

COUP-TFII and NFT<!3 expression are inversely correlated in breast cancer patient

samples
To examine the relationship between COUP-TFII and NFKB in breast cancer
patients, publically available microarray gene expression data from 298 ERu+ patients
treated with tamoxifen for five years was analyzed using the Spearman Rho (pS) statistic
to determine if there was a correlation between COUP-TFII expression and the
expression of NFKB subunits and target genes . COUP- TFII (NR2F2) expression was
inversely correlated with NFKB subunit genes NFKB2 , REL, RELA, and RELB and NFKB
target genes [CAMl, [L6, and TNFAIP3 (Table 4). In contrast, COUP-TFII (NR2F2) was
positively correlated with NFKB target gene CCL2 (Table 4).
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Table 4. Correlation of COUP-TFII expression to NFKB target and subunit gene
expression in ERa+ breast cancer patients treated with tamoxifen.
Spearman correlations of gene expression between COUP-TFII (NR2F2) and select
NFKB-related genes obtained by analysis of micro array data (GSE 17705) from 298
ERa+ breast cancer patients treated with tamoxifen for five years.
Classification
NFKB target

NFKB subunit

Gene
ICAM1
IL6
TNFAIP3
CCL2
NFKB1
NFKB2
REL
RELA
RELB

Spearman
Rho

p-value

-0.35
-0.16
-0.23
0.14

0.0000
0.0063
0.0000
0.0152

0.08

0.1638

-0.20
-0.28
-0.34
-0.12

0.0004
0.0000
0.0000
0.0428
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Correlation to
COUP-TFII
Inverse
Inverse
Inverse
Positive
Inverse
Inverse
Inverse
Inverse

COUP-TFII decreases NFKi3-DNA binding

COUP-TFII can repress gene transcription by direct DNA binding and by direct
protein:protein interaction with other nuclear receptors and transcription factors
[108,226]. To determine if COUP-TFII inhibits NFKB-DNA binding, NE from LCC9
endocrine-resistant cells treated with TNFa to activate NFKB was incubated with
increasing concentrations of in vitro transcribed/translated COUP-TFII protein and a

ePJNFKB RE for an EMSA.
2

In the absence of NE (lane 1), the

ePJNFKB RE did not
2

form a retarded band; however, addition of NE from TNFa-treated LCC9 cells formed a
retarded band (Fig. 18A). The intensity of the NFKB-DNA complex was decreased after
competition with lOO-fold excess of unlabeled NFKB oligomer (Appendix I, Fig. Sll).
COUP-TFII alone did not bind to the

ePJNFKB RE oligomer (Fig. 18A); however, the
2

amount of NFKB retarded complex was first slightly increased and then decreased with
the addition of COUP-TFII in increasing concentrations (Fig. 18A). This suggests that
COUP-TFII directly inhibits NFKB-DNA binding in vitro. A similar effect was seen
using NE from MCF-7 and LCC9 cells transfected with COUP-TFII. In both MCF-7
endocrine-sensitive cells and LCC9 endocrine-resistant cells, trans feet ion with COUPTFII decreased the amount of
was seen in

ePJNFKB RE bound complex (Fig. 18B).
2

No increase

ePJNFKB RE-binding with TNFa treatment in either MCF-7 or LCC9 cells
2

(Fig. 18B), although induction of NFKB activation with TNFa treatment was detected in
LCC9 cells under identical treatment conditions (Fig 13A). These data suggest that
COUP-TFII interacts with and decreases NFKB-DNA complex formation.
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(A) NE (25 flg) from TNFa-treated (6 h) LCC9 cells was incubated alone or with
increasing amounts of in vitro transcribed and translated COUP-TFII. 2PJNFKB RE
DNA probe was added for 1 h prior to EMSA. Values are relative bOlmd 2PJNFKB REI
total 2PJNFKB RE. (B) 25 flg NE prepared from MCF-7 and LCC9 cells transfected
with pcDNA3.1 or pcDNA3.1-COUP-TFII for 48 h and treated with TNFa for 6 h was
incubated with 2PJNFKB RE DNA probe for 1 h to perform EMSA. (A-B) Bottom
2
panels contain lighter exposure of unbound PJNFKB RE DNA probe. (C) TransAM
NFKB family assays were performed to measure NFKB subunit activation using 15 flg
NE from MCF-7 and LCC9 cells transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII
for 48 h and treated with TNFa for 6 h. Values are the average of two determinations ±
SEM. * Significantly different p<O.05 from pcDNA-transfected cells.
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COUP-TFII inhibits RelB, RelA, and p50 NFKB activation

To examine the effect of COUP-TFII on specific NFKB subunit interaction with
the NFKB RE, TransAM NFKB family assays were performed (Fig. 18C). RelB activity
was higher in MCF-7 cells, while NFKB1 p50 activity was greater in LCC9. RelA and cReI activation were not statistically different between the two cell lines. NFKB2 p52
activation was low in MCF-7 or LCC9 (data not shown), consistent with the lack of p52
protein expression seen in western blots (Fig. 17). RelB activation was significantly
decreased by COUP-TFII-transfection in TNFa-treated MCF-7 cells. Activation of RelA
and p50 was inhibited by COUP-TFII in both MCF-7 and LCC9 TNFa-treated cells as
well as untreated LCC9 cells. COUP-TFII inhibited NFKB 1/p50 more than RelA. These
data suggest that COUP-TFII interferes with the binding of NFKB subunits RelB, RelA,
and p50 to the NFKB RE.

COUP-TFII interacts with NFKB subunits

As both COUP-TFII overexpression and in vitro incubation with COUP-TFII
protein led to decrease in NFKB-DNA binding (Fig. 18A and B), reduced p50 and RelB
activation

(Fig.

18C),

and

inhibited

target

gene

expression

(Fig.

15A-D),

co-

immunoprecipitation was used to determine if COUP-TFII interacts with NFKB subunits
to suppress their activity. Imrnunoprecipitation of COUP-TFII in MCF-7 cells revealed
interaction between COUP-TFII and the NFKB subunits RelB and NFkBl p105/p50 (Fig.
19A).
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Figure 19. COUP-TFII interacts with NFKB subunits and inhibits coactivator
function in NFKB activation.
(A) 500 f.1g NE from MCF-7 cells treated with TNFa for 6 h was immunoprecipitated
(IP) using a COUP-TFII antibody and separated on a 10% SDS PAGE gel prior to
transfer to a PVDF membrane. Interaction with NFKB subunits NFKBl p105/p50 and
RelB was identified using specific antibodies on western blot. (B) LCC9 cells were
transfected with a NFKB luciferase reporter and pcDNA3.l or pcDNA3 .l-COUP-TFII for
48 h +/- plasmids for the coactivators SRC-l, SRC-2, SRC-3, and CBP. Cells were
treated with 10 ng/ml TNFa for 6 h before performing dualluciferase assay. Firefly
luciferase values are shown relative to protein concentration for a representative
experiment of quadruplicate values ± SEM. * Significantly different P<0.05 from
pcDNA-transfected cells. Bars connect values which are significantly affected by
COUP-TFII-transfection vs . coactivator alone.
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Inhibition of coactivator function by COUP-TFII reduces NFTd3 transcriptional activity

COUP-TFII has also been reported to reported to inhibit the activity of androgen
receptor (AR) by competing with coactivators for AR interaction [295]. SRC-1, SRC-2, SRC3, and CBP function as coactivators of NFKB-mediated transcription [296]. Each of
these coactivators also have known interactions with COUP-TFII [226]. To determine if
COUP-TFII represses NFKB signaling by interfering with coactivator function, LCC9
cells were cotransfected with a NFKB luciferase reporter with either pcDNA3.1 or
pcDNA3.1-COUP-TFII plasmids (as in Fig. 13A), and plasmids for SRC-1, SRC-2,
SRC-3, or CBP. The cells were treated with 10 ng/ml TNFu for 6 hours to activate
NFKB. SRC-l, SRC-3, and CBP increased NFKB activity in LCC9 cells compared to
parental vector pcDNA (Fig. 19B). SRC-2 transfection had no effect on NFKB activity.
Cotransfection with COUP-TFII decreased the activation of NFKB activity by the
coactivators SRC-1, SRC-3, and CBP (Fig. 19B), implicating COUP-TFII inhibition of
coactivator function, e.g., competing with NFKB for coactivator interaction, as part of the
mechanism of NFKB suppression.

Endocrine-resistant cells are sensitive to NFTd3-inhibition

Cell proliferation assays were performed to determine phenotypic effects of the
both the activation of NFKB pathway in endocrine-resistant cells and the suppression of
NFKB activity by COUP-TFII. MCF-7 and LCC9 cells overexpressing COUP-TFII were
treated with combinations of TNFu to activate NFKB, 4-0HT to assess endocrinesensitivity, and BMS-345541, an NFKB inhibitor that functions by inhibiting IKB kinase
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and subsequent downstream NFKB activation [297].

BMS-345541 treatment was

performed with a range of concentrations (0.01-5 J..lM) determined to be effective in
inhibiting NFKB activity in serum starved MCF-7 and LCC9 cells (Appendix I, Fig. S12).
The proliferation of MCF-7 cells was largely unaffected by treatment with BMS-345541
(Fig. 20A).

MCF-7 cells displayed reduced viability with 4-0HT or combined

transfection with COUP-TFII and 4-0HT treatment (Fig. 20A), as previously reported
[116] and in agreement with MCF-T s phenotype as endocrine-sensitive breast cancer

cells. Treatment with TNFu did not significantly affect the response of MCF-7 to the
compounds tested (Fig. 20B).
When LCC9 cells were treated with increasing concentrations of the NFKB
inhibitor BMS-345541, a marked reduction in cell proliferation was observed (Fig. 20C),
reflecting LCC9's increased reliance on a functional NFKB pathway for cell growth as
endocrine-resistant cells [87,88].

Reduced LCC9 cell viability was observed upon

combined transfection with COUP-TFII and treatment with 4-0HT, as has been
previously reported [116]. LCC9 cells transfected/treated with a combination of COUPTFII, 4-0HT, and BMS-345541 exhibited a reduction in the higher range of BMS345541 concentrations (Fig. 20C). Interestingly, when LCC9 cells were treated with
TNFu, 4-0HT increased cell proliferation (Fig. 20D). This finding could have important
translational implications if tamoxifen therapy may cause similar effects in patients with
high levels of inflammation and NFKB activation. This observed induction of LCC9 cell
proliferation with TNFu and 4-0HT treatment was blocked by transfection with COUPTFII and/or treatment with higher concentrations of BMS-345541 (Fig. 20D).
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Figure 20.
Overexpression of
COUP-TFII increases
endocrine sensitivity in
breast cancer cells.
MCF-7 (A-B) and LCC9
(C-D) cells were serumstarved for 24 h before
being transfected with
pcDNA3.1or
pcDNA3.1-COUP-TFII
for 24 h. Cells were
treated with
concentrations of BMS345541 indicated, as
well as 1 ~ 4-0HT
and 10 ng/ml TNFa for
5 days before
performing MTT assay
to assess changes in cell
proliferation. p<O.05 **
vs . untreated, 1\ vs. 4OHT, # vs. COUP-TFII,
" vs. COUP-TFII + 4OHT, * vs . BMS-only at
each concentration.

DISCUSSION

The NFKB pathway is constitutively activated in many types of cancer, including
breast, gastrointestinal, genitourinary, hematological, and gynecological cancers, through
a variety of mechanisms [86].

NFKB target genes have roles in oncogenic

transformation, including apoptosis resistance [292,298], invasion [299], and epithelial to
mesenchymal transition [300]. Here we demonstrate that COUP-TFII inhibits TNFainduced NFKB activity in LCC9 endocrine-resistant breast cancer cells. Consistent with
previous reports that the NFKB pathway is activated during progression to breast cancer
endocrine-resistance [87,88,91-93,301], LCC9 cells exhibited greater basal and TNFainduced NFKB activity than MCF-7 parental, endocrine-sensitive breast cancer cells.
This inhibition led to downregulation of TNFa-induced NFKB target gene expression of
IL6, ICAM], TNFAIP3, and CCL2, which had reduced basal and/or TNFa-induced

expression upon COUP-TFII overexpression.

The inflammatory cytokine IL6 is a

negative prognostic indicator for breast cancer patients [302], and may have a role in
trastuzumab resistance [303]. Downregulation of the glycoprotein adhesion molecule
ICAM1 at the mRNA and protein levels led to a strong suppression of human breast cell
invasion [304]. The ubiquitin-editing enzyme A20/TNFAIP3 protects MCF-7 cells from
TNFa-induced apoptosis, and cells overexpressing TNFAIP3 are resistant to tamoxifen
[292,298,305].

The chemokine ligand CCL2 may play a role in breast cancer

development and progression, invasion and angiogenesis [299].
NFKB subunit expression is regulated by the NFKB pathway in a positive
feedback loop. Specifically, RelA activates expression of RelB [306] and NFKB2 [307],
while NFKB l/p50 expression is regulated by a combination of p50 and RelA [308].
99

Similarly, c-Rel is also capable of autoregulation [309]. Because COUP-TFII suppresses
genes that are targets of the NFKB pathway, this would also lead to reduced expression of
the NFKB subunits as observed. Consistent with our data showing higher NFKB subunit
and target gene expression in LCC9 endocrine-resistant cells, NFKB subunits NFKBl,
NFKB2, RELA, and REL as well as the NFKB gene targets [CAMl, TNFA[P3, and CCL2

are also upregulated in inflammatory breast cancer patient samples [310]. A previous
study showed that overexpression of COUP-TFII inhibited 15d-PGJ2-induced IL-8
rnRNA expression and promoter activity in U937 human myeloid cells, a result which the
authors attributed to COUP-TFII competing with PPARy to form a heterodimer with
RXR or by forming a COUP-TFIIIRXR heterodimer and competing with PPARylRXR
for DNA binding [311].
COUP-TFII was recently identified as one of four NRs that are significant
predictors of metastasis-free survival in tamoxifen-treated breast cancers, independent of
ERa expression [85]. We previously observed that COUP-TFII expression was reduced
with histological grade [115] and this was confirmed in [85]. Here we report for the first
time that COUP-TFII, i.e., NR2F2 gene expression was inversely correlated with NFKB
subunit genes NFKB2, REL, RELA, and RELB and NFKB target genes [CAMl, [L6, and
TNFAIP3 in microarray data from 298 ERa+ breast tumors from patients treated with

TAM for five years (Table 4). Although COUP-TFII inhibited NFKB target gene CCL2
in LCC9 cells (Fig. 15), COUP-TFII (NR2F2) was positively correlated with CCL2 in the
breast tumors (Table 4), indicating potential differences between the patient population
and cell line responses.

This might be due to the effect of the breast tumor
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microenvironment in the patients, and expression of CCL2 by tumor-associated
macrophages and other cells [299].
Mechanistically, I have demonstrated that COUP-TFII interacts with NFKB
subunits RelB and NFKBI p105/p50 and inhibits NFKB DNA-binding. COUP-TFII also
inhibited the ability of coactivators SRC-l, SRC-3 , and CBP to enhance NFKB
activation. The effects of COUP-TFII on NFKB lead to inhibition of cell proliferation,
with endocrine-resistant LCC9 cell proliferation showing the most reduction when treated
with an NFKB inhibitor. Overall, these data indicate a general downregulation of NFKB
target gene expression by COUP-TFII, which could have important phenotypic
consequences on endocrine sensitivity.

As NFKB is highly activated in endocrine-

resistant cells, blockage of downstream target gene expression by COUP-TFII may be a
mechanism by which COUP-TFII enables breast cancer cells to maintain endocrine
sensitivity.

Natural product inhibitors of NFKB activity such as parthenolide [88],

curcumin [312,313], and ellagic acid [314] , as well as synthetic inhibitors [89,297]
provide compounds for both experimental and future translational purposes. These data
point to potential for the combination of NFKB inhibitors with antiestrogen therapies, e.g.
tamoxifen, to promote endocrine sensitivity, as well as the availability of COUP-TFII as
a marker for response.
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CHAPTER V - IDENTIFICATION OF COUP-TFII-INTERACTING PROTEINS
IN TAMOXIFEN-TREATED BREAST CANCER CELLS

INTRODUCTION

COUP-TFIl is an orphan nuclear receptor that may play multiple roles in
endocrine resistance.

COUP- TFII expression is reduced in endocrine-resistant breast

cancer cell lines, and overexpression of COUP-TFII restores endocrine sensitivity [116].
Part of the mechanism of maintenance of endocrine sensitivity by COUP- TFII involves
its ability to suppress activation of NFKB pathway, as described in Chapter IV.

As

detailed in Chapter II, many pathways have been reported to be amplified in endocrine
resistance and play important roles as both prognostic indicators and areas for potential
therapeutic intervention, such as COUP- TFIL As outlined in previous chapters, the role
of COUP-TFII in multiple pathways involved in cell differentiation, apoptotic resistance,
migration, invasion, and others seems to be dependent on cellular context and interacting
partners [226].
Mass spectrometry-based analyses to identify protein interactions can yield
important information about disease states [315]. Protein interaction networks provide
detailed pathways to enhance understanding of a protein in a particular cellular context
[316]. Analyzing the roles of proteins within a particular protein complex or network
produces valuable information about the specific activities of the proteins within the cell
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[317].

Proteomics is especially useful when studying drug resistance, resulting in

additional angles from which to target a particular pathway [317].

As described in

Chapter III, a previous study to identify COUP-TFII-interacting proteins in MCF-7 cells
identified nucleolin as a coactivator for COUP-TFII-mediated transcription of retinoic
acid receptor B2 (RARB2) [115].
The focus of the present study was to identify proteins that interact with COUPTFII in ethanol- versus tamoxifen-treated MCF-7 cells to define interacting proteins
changed by treatment with tamoxifen. The goal of this study was to better understand the
function of COUP-TFII in maintenance of breast cancer cellular response to tamoxifen
treatment and how loss of COUP-TFII expression confers endocrine resistance to breast
cancer cells.

Heat shock protein 27 (HSP27) was identified amongst the proteins

interacting with COUP-TFII more strongly in tamoxifen-treated cells. Given conflicting
reports linking HSP27 to both increased and decreased drug resistance [318-325], HSP27
was selected for additional studies.
HSP27 interaction with COUP-TFII was confirmed in MCF-7 breast cancer cells
by co-immunoprecipitation experiments. Regulation of HSP27 expression by estradiol
and tamoxifen was investigated, as well as the expression and phosphorylation of HSP27
in both endocrine-resistant and trastuzumab-resistant breast cancer cells. Further studies
are necessary to fully determine the relationship between HSP27 and COUP-TFII.

MATERIALS AND METHODS

Chemicals and antibodies
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4-hydroxytamoxifen (4-0HT) and

17~-estradiol

(E2) were purchased from Sigma-

Aldrich (St. Louis, MO). The following antibodies were purchased: polyclonal COUPTFII (Abcam, Cambridge, MA); monoclonal (rnAB) anti-human COUP-TFII (R&D
systems, Minneapolis, MN; PP-H7147-00); mAB anti-FLAG M2 and

~-actin

(Sigma-

Aldrich); mAB HSP27 (Santa Cruz, Santa Cruz, CA), polyclonal phospho-HSP27
(Ser82) and mAB HER2 (c-ErbB2/c-Neu, Millipore, Billerica, MA), HRP-conjugated
secondary antibodies were from GE Healthcare (Piscataway, NJ).

Cell culture

MCF-7 breast cancer cells were purchased from ATCC and used at passage < 10.
Endocrine-resistant LCC2 [326], LCC9 [285], and LY2 [327] breast cancer cells were
obtained from Robert Clarke (Georgetown University). MCF-7, LCC2, LCC9, and LY2
cells were maintained in improved MEM (IMEM) (Cellgro, Manassas, VA)
supplemented with 5% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville,
GA) and 1% penicillin/streptomycin (PIS, Cellgro). JIMT-l trastuzumab-resistant breast
cancer cells [328] were obtained from Gail Sonenshein (Tufts University) and maintained
in DMEM (Cellgro) supplemented with 10% FBS and 1% PIS. All cells were maintained
in a 37°C incubator containing 5% CO2 .

Immunoprecipitation of CO UP- TFII-FLAG-interacting proteins

MCF-7 cells were transfected with pIRES-COUP-TFII-FLAG for 24 h using
FuGENE HD (Roche, Indianapolis, IN) according to manufacturer's instructions. Cells
were 'serum-starved' using phenol red-free IMEM supplemented with 5% dextran-coated
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charcoal-stripped serum (Atlanta Biologicals) for 24 h before being treated with 100 nM
4-0HT or vehicle control EtOH for 2 h. One mg of whole cell extract (WCE) prepared in
lysis buffer (10% glycerol, 50 rnM HEPES pH 8.0, 100 mM KCI, 2 rnM EDTA, 0.1%
NP-40, 2 rnM DTT, protease inhibitor cocktail (Roche), 10 mM NaF, and 0.25 rnM
NaV0 4 )

[329] was incubated with EZview™ Red ANTI-FLAG® M2 Affinity gel

(Sigma-Aldrich) for 4 h at 4°C with constant rotation.

Washes and elution was

performed in spin chromatography columns (BioRad, Hercules, CA).

COUP-TFII-

FLAG-interacting proteins were eluted by incubation with 100 III 6M urea + 100rnM
(N~)HC03

for 30 min with constant rotation. Three elution volumes were subsequently

pooled for further analysis.

Identification of CO UP- TFII-interacting proteins by 2D-LC-MSIMS
COUP-TFII-FLAG protein complexes were analyzed with a Thermo LTQ linear
ion trap using a previously described 2D-LC-MSIMS approach [329].

Database

searching was performed with tandem mass spectra extracted by ReadW and converted to
mzXML format. Charge state deconvolution and deisotoping were not performed. All

MSIMS samples were analyzed using SequestSorcerer (Sage-N, Milpitas, CA). Sequest
was set up to search a FASTA-formatted human protein database (Human RefSeq, 2007).
Searches were performed with a fragment ion mass tolerance of 1.00 Da and a parent ion
tolerance of 1.2 Da. Iodoacetamide derivative of cysteine was specified as a fixed
modification. Oxidation of methionine was specified as a variable modification.
Scaffold (version Scaffold 3.0.00, Proteome Software Inc., Portland, OR) was
used to validate MSIMS based peptide and protein identifications. Protein probabilities
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were assigned by the Protein Prophet algorithm [330].

Protein identifications were

accepted if they could be established at greater than 95.0% probability. Proteins that
contained similar peptides but could not be differentiated based on MSIMS analysis alone
were grouped to satisfy the principles of parsimony.

Co-immunoprecipitation (co-IP) and immunoblotting

Nuclear and cytosolic proteins were prepared as in Chapter III [115].

4!J.g

COUP-TFII polyclonal antibody (Abcam) or rabbit IgG (Invitrogen, Carlsbad, CA) were
added to 50 !J.I Dynabeads Protein A (Invitrogen) in PBS (Cellgro) for 20 min at 4°C.
400 !J.g NE was added and incubated for 4 h at 4°C with rotation. Beads were washed 3x
with PBS and bound proteins were eluted by incubation with Elution Buffer (Invitrogen).
Proteins were separated by SDS-PAGE and analyzed by western blot [115,116].

Cell treatment

Cells were 'semm-starved' for 48 h pnor to treatment with ethanol (EtOH,
vehicle control), 10 nM E2 , or 100 nM 4-0HT for 6 h, as indicated.

RNA Isolation, RT-PCR and Quantitative Real-Time-PCR (QRT-PCR)

RNA isolation, cDNA preparation, and QRT-PCR were performed as in [115].
QRT-PCR for HSP27 (HSPBl) and 18S, used Taqman Gene Expression Assays
(Invitrogen). COUP-TFII (NR2F2) and GAPDH were measured using the SYBR green
method as in [116]. All QRT-PCR was performed in the ViiA 7 Real-Time PCR system
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(Applied Biosystems, LifeTechnologies). Fold change was calculated from the
values with the formula

2-~~CT

~~CT

and data are relative to EtOH-treated cells.

Statistical analysis
Values are reported as ± SEM. Student's t test was used for comparisons between
control and treatment. P values considered statistically significant are indicated.

RESULTS
Identification of CO UP- TFII-associated proteins in ethanol- and tamoxifen-treated cells
To identify COUP-TFII-interacting proteins which are increased in their
association with COUP-TFII either in EtOH (vehicle control) or 4-0HT treated MCF-7
cells, 2D-LC-MSIMS was performed following immunoprecipitation of COUP-TFIIFLAG and interacting proteins from EtOH and 4-0HT-treated MCF-7 cells. Efficiency
of FLAG affinity purification is demonstrated in Figure 21. The majority of COUP-TFIIFLAG was bound by the FLAG affinity gel and not lost in flow through or washes
(Figure 21A). COUP-TFII-FLAG was detected by western blot in both EtOH and 4OHT-treated cells and not in vector control-transfected cells (Figure 21B). From the
mass spectrometry analysis, proteins were identified as interacting with COUP-TFII
specifically in EtOH or 4-0HT-treated cells, as well as a group of proteins which were
found in both EtOH and 4-0HT treated samples to varying degrees (Table 5). While
three independent IP-mass spectrometry experiments were performed, COUP-TFII was
not identified in the second experiment, and data from this experiment were not included
in the summary of proteins identified as interacting with COUP-TFII.
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COUP-TFII-

interacting proteins (from experiments 1 and 3) were subsequently categorically assigned
as enriched in the ethanol or tamoxifen-treated groups, or equal/indistinguishable
between the two (Table 5) based on their overall presence (number of spectra) in the
replicate experiments.
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Figure 21. Efficiency of COUP-TFII-FLAG purification by FLAG affinity gel.
A, 20 Jlg WCE from MCF-7 cells transfected with COUP-TFII-FLAG (input), 25 Jll flow
through from incubation of WCE with FLAG affinity gel, 25 Jll IF washes , and 10 Jll of
elutions 1 and 2 (10% of elution volume) were analyzed by western blot to detect the
presence of COUP-TFII-FLAG. B, 20 Jlg WCE from empty vector pIRES or COUPTFII-FLAG-transfected cells treated with EtOH or 4-0HT (input) or 10 Jll of pooled
elutions 1-3 were analyzed by western blot to detect the presence of COUP-TFII-FLAG
before and after immunoprecipitation.
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Table 5. COUP-TFII-interacting proteins in ethanol- and tamoxifen-treated MCF-7
cells.
COUP-TFII-FLAG-transfected MCF-7 cells were treated with EtOH (Et) or 100 nM 4OHT (T) for 2 h. 1 mg WCE was incubated with anti-FLAG affinity gel. COUP-TFIIFLAG and interacting proteins were eluted with 6 M urea and 100 mM (NH4)HC03. 2DLC-MS/MS was used to identify proteins. The number of assigned spectra for identified
proteins (Values) was normalized to number of spectra for COUP-TFII (bottom row in
this Table) in each experiment. Qualitative assignment to ethanol, tamoxifen, and equalinteracting groups was made based on normalized values.
Experiment 1
Values Normalized

Experiment 2
Values Normalized

Et

T

Et

T

Et

T

Qualitative
enrichment

102 24

3.00

0.67

10

4

3.33

4.00

Ethanol

2

0.12

0.06

11

2

3.67

2.00

Ethanol

0.29

7

2

2.33

2.00

Ethanol

4

MW

Identified Proteins

(kOa)

Et

T

myosin-9 (MYH9)
spectrin alpha chain
(SPTAN1)

227
285

4

Calmodulin (CALM)
spectrin beta chain
(SPTBN1)

17

10

275

4

0

0.12

50

41

50

1.21

1.39

6

53

25

26

0.74

0.72

6

69

10

8

0.29

0.22

2

2

0.67

2.00

Tamoxifen

89

9

10

0.26

0.28

2

2

0.67

2.00

Tamoxifen

59

65

59

1.91

1.64

2

2

0.67

2.00

Tamoxifen

12

4

5

0.12

0.14

2

2

0.67

2.00

Tamoxifen

69

28

27

0.82

0.75

2

2

0.67

2.00

Tamoxifen

28

14

16

0.41

0.44

2

2

0.67

2.00

Tamoxifen

71

48

53

1.41

1.47

2

4

0.67

4.00

Tamoxifen

72

23

30

0.68

0.83

2

2

0.67

2.00

Tamoxifen

23

10

14

0.29

0.39

2

2.00

Tamoxifen

33

6

3

0.18

0.08

2

2.00

Tamoxifen

11

34

27

1.00

0.75

8

4

2.67

4.00

Equal

filamin-A (FLNA)

280

35

40

1.03

1.11

8

2

2.67

2.00

Equal

myosin-14 (MYH14)

228

7

4

2

1.33

2.00

Equal

tubulin alpha-1 B chain
(TUBA1B)
RNA-binding protein
FUS (FUS)
serum albumin
preproprotein (ALB)
heterogeneous nuclear
ribonucleoprotein U
(HNRNPU)
keratin, type I
cytoskeletal 10 (KRT10)
60S acidic ribosomal
protein P1 (RPLP1)
probable ATPdependent RNA
helicase DDX5 (DDX5)
homeobox prox 1
(PROX1)
heat shock cognate 71
kDa protein (HSPA8)
78 kDa glucoseregulated protein
precursor (HSPA5)
heat shock protein beta1 (HSPB1)
F-actin-capping protein
subunit alpha-1
(CAPZA1)
histone H4 (HIST1 H4)

0.21

110

1.33

10

2.00

Ethanol

10.00

2.00

Tamoxifen
Tamoxifen

keratin, type II
cytoskeletal 8 (KRT8)

54

77

93

2.26

2.58

5

2

1.67

2.00

Equal

myosin-Ib (MY01 B)
keratin , type I
cytoskeletal 9 (KRT9)
2,4-dienoyl-CoA
reductase, mitochondrial
precursor (DECR1)
keratin, type II
cytoskeletal 1 (KRT1)

125

8

1

0.24

0.03

4

2

1.33

2.00

Equal

62

63

38

1.85

1.06

2

2

0.67

2.00

Equal

36

6

6

0.18

0.17

3

1

1.00

1.00

Equal

66

53

47

1.56

1.31

myosin-Ic (MY01 C)
X-ray repair crosscomplementing protein 6
(XRCC6)
plasminogen activator
inhibitor 1 RNA-binding
protein (SERBP1)

122

4

70

59

56

1.74

1.56

45

21

21

0.62

0.58

46

34

36

1.00

1.00

COUP transcription
factor 2 (NR2F2)

0.12

111

0.33

Equal

3

1.00

Equal

3

1.00

Equal
1.00

3

1.00

1.00

Equal

Functional Annotation Clustering of CO UP- TFII-interacting proteins

The Database for Annotation, Visualization, and Integrated Discovery (DAVID,
version 6.7) [331,332] was used to identify functionally related groups amongst the
identified COUP-TFII-interacting proteins in the ethanol, tamoxifen, and equally
enriched groups (Table 6). This bioinformatic analysis allows for detection of biological
themes amongst groups of proteins to identify pathways that may be relevant in a
particular state [331,332]. Gene lists compiled from Table 5 were entered into the
DA VID database and functional annotation clustering was performed using high
stringency for analysis. Repeated terms were removed from the resulting list (Table 6).
Common themes amongst the groups were calmodulin-binding (ethanol and
equal) and RNA splicing/alternative splicing (ethanol and tamoxifen) (Table 6),
suggesting these may have importance to COUP-TFII. As calmodulin was identified
amongst the COUP-TFII-interacting proteins (Table 6), this may indicate that this
interaction has significance. A role for COUP-TFII in RNA splicing has not yet been
reported, and this may also be a new area for study given potential interactions with
DEAD box protein 5 (DDX5), RNA-binding protein PUS (PUS), and heterogeneous
nuclear ribonucleoprotein U (HNRNPU) with tamoxifen treatment (Table 5 and 6).
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Table 6. Functional Annotation Clustering ofCOUP-TFll-interacting proteins.
Proteins identified as enriched in the EtOH or tamoxifen-treated samples or proteins
identified as interacting with COUP-TFII relatively the same with either treatment were
entered into the DAVID database to identify biological relationships between the
proteins.
Term

Count

p-value

Fold
Enrichment

Bonferroni

3
3
3
3
3
3

4.3E-05
1.2E-04
1.2E-04
4.9E-04
7.9E-02
3.4E-Ol

195.64
120.22
115.50
58.41
4.35
1.93

0.003
0.004
0.008
0.018
0.996
1.000

4
4
4
4
4
4

5.8E-05
2.6E-03
8.4E-03
2.6E-02
5.4E-02
2.2E-Ol

25.76
7.30
4.92
3.38
2.65
1.67

0.002
0.091
0.435
0.831
0.871
1.000

3

0.018

12.99

0.918

5

0.012

4.75

0.568

3

0.027

10.42

0.978

3

0.079

5.81

0.997

4

0.036

4.84

0.923

ETHANOL
Cluster 1: MYH9, SPTAN1, SPTBNl
Cortical cytoskeleton
Calmodulin-binding
Cell cortex
Actin-binding
Plasma membrane part
Alternative splicing
Cluster 2: MYH9, SPTAN1, CALM, SPTBN1
Cytoskeletal protein binding
Acetylation
Non-membrane-bounded organelle
Plasma membrane
Phosphoprotein
Polymorphism

TAMOXIFEN
Cluster 1: DDXS, FUS, HNRNPU
RNA splicing
Cluster 2: DDXS, HSPA8, HNRNPU, TUBAIB,
HSPAS
Nucleotide-binding
Cluster 3: ALB, HSPB1, HSPAS
Negative regulation of apoptosis
Cluster 4: ALB, HSPA8, HSPAS
Cytoplasmic membrane-bounded vesicle
Cluster 5: DDXS, HSPA8, HNRNPU, HSPAS
ATP-binding
Cluster 6: ALB, FUS, HSPAS
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Metal ion binding

3

0.910

0.78

1.000

3
3

3.1E-04
9.5E-04

102.86
57.44

0.019
0.026

4
4

2.3E-04
5.7E-03

28.32
9.37

0.015
0.310

3
3
3

7.2E-04
1.8E-03
8.3E-02

67 .26
40.42
5.58

0.044
0.013
0.996

4
4

2.7E-02
5.1E-02

5.27
4.15

0 .824
0.962

3
3

1.5E-01
4.2E-01

3.95
1.96

1.000
1.000

EQUAL
Cluster 1: MY01B, MY01C, MY014

Myosin
Calmodulin-binding region
Cluster 2: MYOIB, MY01C, MY014, FLNA

Actin-bind ing
Cytoskeletal protein binding
Cluster 3: KRTl, KRT8, KRT9

Intermediate filament
Cytoskeletal keratin
Structural molecule activity
Cluster 4: MYOIB, MY01C, MY014, XRCC6

ATP-binding
Nucleotide-binding
Cluster 5: XRCC6, HISTlH4, MY01C

Nucleoplasm
Intracellular organelle lumen
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Endogenous nuclear interaction of COUP-TFlI with HSP27

Heat shock protein beta-l (HSPBl), also known as heat shock protein 27
(HSP27), is a member of the small heat shock protein family of chaperones that are
involved in maintenance of protein stability and prevention of abnormal protein folding
or aggregation [333,334]. HSP27 is increased expression in breast carcinoma and other
cancers and can inhibit caspase-dependent apoptosis [335-337]. HSP27 expression has
been reported to be increased by chemotherapy in breast cancer patients and to be
correlated with reduced disease free survival [318].
ER~

HSP27 is known to interact with

[338], ERa, progesterone receptor (PR), and androgen receptor (AR) [339]. Based

on these reports, HSP27 was selected from the list of proteins identified to interact with
COUP-TFII, and enriched in cells treated with 4-0HT, for further investigation.
Endogenous COUP-TFII-HSP27 interaction was examined in MCF-7 cells.
HSP27 is abundantly present in both the NE and CE of MCF-7 cells, while COUP-TFII is
only present in the NE (Fig. 22A). HSP27 was detected via western blot following IP of
NE with a polyclonal COUP-TFII antibody (Fig. 22A). No HSP27 was present in the
negative control IgG or antibody-only lanes (Fig. 22A). Interaction of COUP-TFII with
calmodulin, another protein identified by mass spectrometry to interact with COUP-TFII,
although enriched when cells were treated with EtOH (Table 5), was also verified
through IP (Fig. 22A).
To examine whether COUP-TFII-HSP27 interaction was altered following
treatment with 4-0HT, a similar IP was performed using NE prepared from MCF-7 cells
treated with EtOH (vehicle control) or 4-0HT for 2 h (Fig. 22B). No significant change
in COUP-TFII-HSP27 interaction was observed following treatment with 4-0HT as
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compared to EtOH (Fig. 22B).

COUP-TFII and HSP27 expression and subcellular

localization were also not affected by treatment (Fig. 22B). COUP-TFII interaction with
calmodulin was also verified via IP in MCF-7 cells (Fig. 22A), although follow-up
experiments to elucidate the function of this interaction have not yet been performed.
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Figure 22. Endogenous nuclear interaction of COUP-TFII with HSP27 and
calmodulin in MCF -7 cells.
400 ).1g NE from MCF-7 cells was immunoprecipitated with polyclonal COUP-TFII
antibody or negative control rabbit IgG (negative control) and analyzed by western blot
for COUP- TFII and interacting proteins identified via mass spectrometry. 40).1g NE or
CE was used as input control. A, COUP- TFII interacts with HSP27 and calmodulin in
MCF-7 cells. B, COUP- TFII interacts with HSP27 in EtOH and 4-0HT -treated MCF-7
cells.
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Regulation of HSP27 by estradiol and tamoxifen in endocrine-resistant breast cancer
cells

The promoter region of HSP27 contains a Spl and half ERE site reported to be
responsible for the upregulation of HSP27 expression by E2 through a SpllER complex
[340]. To examine both the relative expression of HSP27 in breast cancer cell lines with
increasing endocrine resistance, as well as the effect of E2 and 4-0HT treatment on
HSP27 expression, MCF-7, LCCl, LCC2, LCC9, and LY2 cells were treated with 10 nM
E2, 100 nM 4-0HT, or EtOH (vehicle control) for 6 h. Increased HSP27 expression was
observed in LCCl estrogen-independent but tamoxifen-sensitive cells [326] as compared
to MCF-7 estrogen-dependent, tamoxifen-sensitive cells. LCC2 cells, which are both
estrogen-independent and tamoxifen-resistant [326], had reduced HSP27 expression
compared to MCF-7. LCC9, estrogen-independent, tamoxifen and fulvestrant-resistant
cells [285], displayed a further reduction in HSP27 expression. LY2, a breast cancer cell
line that is resistant to tamoxifen, fulvestrant, and LY1170l8 (a raloxifene analog) [327]
and has lmdergone epithelial to mesenchymal transition, had undetectable expression of
HSP27 by QRT-PCR.
Previous reports have indicated regulation of HSP27 by estrogen signaling [340];
however, this was not confirmed in these experiments. E2 treatment had no statistically
significant effect on HSP27 expression in any of the cell lines examined (Fig. 23),
reflecting potential differences the breast cancer cell lines used by investigators, the
methods of detection, altered endocrine responses of the tamoxifen-resistant cell lines,
etc. 4-0HT treatment in LCCl cells lead to a slight increase in HSP27 expression (Fig.
23)" while no effect was observed in other cell lines. Increased HSP27 expression in
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response to 4-0HT treatment would be consistent with reports that cellular stress and
drug treatment induce HSP27 expression [336,341].

HSP27 and COUP-TFII expression is reduced in endocrine-resistant and trastuzumabresistant breast cancer cells
To follow up on the observed differences in steady state mRNA expression of

HSPBl (Fig. 23), HSP27 expression was also analyzed by western blot of WCE from
endocrine-sensitive MCF-7 cells and endocrine-resistant LCC2, LCC9, and LY2 cells.
As seen at the mRNA level (Fig. 23), a reduction in HSP27 expression was prominent in
LY2 cells (Fig. 24A). LCC2 and LCC9 cells displayed HSP27 expression approximately
equivalent to MCF-7 cells. Interestingly, the lower molecular weight band of HSP27
seen in MCF-7, LCC2, and LCC9 was absent in LY2 cells (Fig. 24A). HSP27 expression
was also examined in a trastuzumab-resistant breast cancer cell line, JIMT-l (Fig. 24B).
Trastuzumab (Herceptin) is a monoclonal antibody used for the treatment of HER2+
breast cancer patients [12]. JIMT -1 cells display clinical resistance to trastuzumab, as
they were derived from a pleural effusion of a patient whose disease had progressed to
trastuzumab-resistance [328]. Similar to LY2 cells, HSP27 expression was reduced in
JIMT-l cells, and the lower band seen in MCF-7 cells was not present (Fig. 24B).
Phosphorylation of HSP27 by MAPK at serine 15, 78, and 82 has also been
shown to be important to its cellular function and localization [319,325]. Cell stress,
such as heat shock, chemotherapy, or cytokine exposure, can induce phosphorylation of
HSP27 [337]. Phosphorylation of HSP27 at Ser82 was also examined in the same cell
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lines, and the pattern of p-Ser82-HSP27 was found to mirror the expression of HSP27 in
all 5 cell lines examined (Fig. 24A and B).
To investigate a possible correlation between HSP27 and COUP-TFII expression,
COUP-TFII expression was also analyzed by western blot. As previously reported [116],
COUP-TFII expression is reduced in the endocrine-resistant LCC2, LCC9, and LY2 cells
as compared to MCF-7 (Fig. 24A). COUP-TFII expression was also much lower in
JIMT -1 cells compared to MCF-7 endocrine-sensitive cells, suggesting a potential role
for COUP-TFII in trastuzumab-resistance (Fig. 24B).

COUP-TFIIIHSP27 and HER2 expression are inversely correlated

We have previously reported an inverse correlation between COUP-TFII and
HER2 expression in tamoxifen-treated patient tumors via immunohistochemistry [115].
To determine if COUP-TFII and HSP27 expression are correlated to HER2 expression in
the endocrine-resistant and trastuzumab-resistant cell lines, a western blot was performed
using a HER2 antibody. HER2 expression was undetectable in MCF-7 and LCC2 cells
(Fig. 24A). Very low expression of HER2 was detected in LCC9 cells, while LY2 cells
had the greatest HER2 expression of the endocrine-resistant cell lines (Fig. 24A). JIMT1 cells are trastuzumab-resistant and, as part of their identified phenotype, have been
reported to have increased expression of HER2 [328]. JIMT -1 cells had the highest
HER2 expression detected in any of the cell lines examined (Fig. 24B). These data
suggest a trend towards an inverse pattern of expression between COUP-TFIIIHSP27 and
HER2 in the cell lines examined herein.
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Figure 23. Regulation of HSP27 expression by E2 and 4-0HT in TAMS and T AMR
cells.
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DISCUSSION

The role of HSP27 in breast cancer response to antiestrogens and other treatments
has been controversial. Examination of HSP27 expression by immunohistochemistry in
ERu+ tamoxifen-treated breast cancer patients with metastatic disease revealed no
statistically significant association between HSP27 and response to tamoxifen therapy
[320]. This is in contrast to an early study which reported that patients with HSP27+
tumors responded better to tamoxifen and had a lower failure rate than patients with
HSP27- tumors, implicating loss of HSP27 in progression to tamoxifen-resistance [321].
Another group reported increased resistance to doxorubicin in MDA-MB-231 cells
overexpressing HSP27 [342]. However, HSP27 expression was reduced in doxorubicinresistant MCF-7/adr cells.

This was also correlated to reduced heat shock factor 1

expression and increased NFKB p65 and mutant p53 expression in the MCF-7/adr cells
[324].

A trastuzumab-resistant cell line, SKBR3 HR, expresses increased levels of

HSP27 compared to the parental SKBR3 cell line. Knockdown of HSP27 expression
resulted in increased trastuzumab sensitivity, although no correlation between HSP27 and
trastuzumab sensitivity could be established across a panel of cell lines [322]. Further
evaluation of the reduced HSP27 expression in endocrine-resistant and trastuzumabresistant breast cancer cells (Fig. 24A and B) and the interaction of HSP27 with COUPTFII (Fig. 22A and B) identified herein may provide more clues. Evaluation of the

specific identity of the lower molecular weight band of HSP27 present in MCF-7, LCC2,
and LCC9 but not LY2 and JIMT -1 cells (Fig. 24A and B) may also be of interest.
The phosphorylation status of HSP27 may also contribute to its ability to
modulate chemoresistance [322,323].

Decreased phosphorylation of HSP27 at Ser82
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with increasing endocrine resistance or trastuzumab resistance corresponding to
decreased HSP27 expression was identified in this study (Fig. 24A-B), but
phosphorylation of other sites may also be important.

Phosphorylation of HSP27 at

Ser78 is regulated downstream of the HER2-p38 MAPK pathway [343], and may also
play a role in trastuzumab sensitivity.

Induction of apoptosis was associated with

increased phosphorylation of HSP27 in response to TNFa or 4-0HT treatment,
suggesting HSP27 phosphorylation may play a role in treatment response [325].
Phosphorylation

of

HSP27

also

increases

its

nuclear

translocation,

unphosphorylated HSP27 remams distributed throughout the cell [319].

while

It would be

interesting to see if phosphorylation plays a role in HSP27 interaction with COUP-TFII.
Much remains to be determined about the role of phosphorylation in HSP27 function and
effect on drug sensitivity. Further investigation into whether phosphorylation of HSP27
is tumor-promoting or tumor-suppressive will yield insight into the complex cellular
actions of HSP27.
In addition to HSP27, other cancer-associated proteins were found to interact with
COUP-TFII through this proteomic study, which will require further investigation. The
interaction between COUP-TFII and calmodulin was also verified herein (Fig. 22A).
Calmodulin, a calcium binding protein, also interacts with EGFR [344], HER2 [345],
ER~

[346], and ERa [347,348]. Binding of calmodulin to ERa stabilizes ERa [349], and

tamoxifen inhibits the interaction of ERa and calmodulin [350]. Calmodulin appears to
play a role in HER2 stimulated SKBR3 cell proliferation since calmodulin inhibition
decreased HER2-stimulated cell growth [345]. Further investigation of the function of
the interaction between COUP-TFII and calmodulin would be of interest. Also found to
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interact with COUP-TFII was DEAD box protein 5 (DDX5), which interacts with ERa
where it functions as a transcriptional coactivator [351]. DDX5 also interacts with other
ERa and COUP-TFII coactivators SRC-1, SRC-2, and SRC-3 [352]. Interaction between
DDX5 and COUP-TFII has not yet been reported, but would be another potential area to
pursue.
In conclusion, novel COUP-TFII-interacting proteins have been identified
through a proteomic screen and their relative interaction with COUP-TFII following
treatment with EtOH or 4-0HT has been qualitatively analyzed. COUP-TFII-HSP27
interaction in MCF-7 cells and reduced expression of HSP27 in endocrine-resistance and
trastuzumab-resistance raises many questions about the function of these proteins in
breast cancer cells. Of particular interest will be analyses of HSP27 localization and
phosphorylation in endocrine-resistant and trastuzumab-resistant cells, and the effect of
COUP-TFII on these properties.
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CHAPTER VI - RESEARCH IMPLICATIONS

Breast cancer is the most common type of cancer diagnosed in women and the
second leading cause of female cancer death [4]. The use of antiestrogen therapy such as
selective estrogen receptor modulators (SERMs) greatly increases survival, with five
years of tamoxifen therapy reducing mortality rate by 32% and recurrence rate by 45%
[50].

Despite the initial efficacy of this treatment, approximately 40% of patients

undergoing antiestrogen therapy progress to metastatic disease and die [56].
Identification of novel treatment combinations, biomarkers, and drug targets is of great
importance in increasing the effectiveness of antiestrogen therapy for patients. In this
study, I have described the function of the orphan nuclear receptor COUP-TFII in breast
cancer and endocrine resistance.
COUP-TFII-interacting proteins in MCF-7 breast cancer cells were identified in
studies described in Chapter III. The interaction between COUP-TFII and nucleolin was
verified through co-immunoprecipitation and an in vitro binding assay [115]. Nucleolin
is a multifunctional protein that has roles in mRNA stability, ribosome biogenesis,
apoptosis, and the modulation of gene expression as a coregulator [253-257]. As COUPTFII transcriptional action is largely modified by interaction with coregulators [226], a
role for nucleolin as a coregulator for transcription of a COUP-TFII-regulated gene
retinoic acid receptor B2 (RARB2) was explored.
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Nucleolin enhanced COUP-TFII

activated RARB2 expressIOn, and siRNA-mediated knockdown of COUP-TFII or
nuc1eolin reduced RARB2 expression [115]. This indicates that both COUP-TFII and
nuc1eolin are necessary for the basal expression of RARB2. Binding of COUP-TFII to
the promoter of RARB2 was also verified, as well as COUP-TFII regulation of a
RARB2-target gene, retinoid receptor-induced gene-1 (RRIG1) [115].

Supporting

evidence for the importance of COUP-TFII in breast cancer was provided by
immunohistochemical (rnC) staining of breast cancer tumor tissue microarrays,
where an inverse correlation was found between COUP-TFII expression and tumor
grade. COUP-TFII and nuc1eolin expression were also positively correlated in ERa+
invasive ductal carcinomas [115].

These data enhance our understanding of the

regulation of COUP-TFII' s transcriptional activity, as well as the characteristics of
COUP-TFII expression in breast cancer tissue.
Several reports have implicated increased NFKB activity as a driving pathway
in endocrine-resistance breast cancer [87,88,280-284]. As COUP-TFII expression is
reduced in endocrine-resistant breast cancer, and COUP-TFII can repress the activity
of other transcription factors, Chapter IV explores a role for COUP-TFII in
suppression of NFKB activity in breast cancer.

Endocrine-resistant LCC9 cells

displayed much greater basal and TNFa-induced NFKB activity than endocrinesensitive MCF-7 cells. Transfection of COUP-TFII in endocrine-resistant LCC9 cells
reduced NFKB activation. COUP-TFII suppressed both the basal and TNFa-induced
expression of NFKB target genes IL6, CCL2, ICAM1 , and TNFAIP3 in LCC9 cells, as
well as the basal expression of ICAM1 and TNFAIP3 and the TNFa-induced CCL2
and TNFAIP3 in MCF-7 cells. COUP-TFII also suppressed the basal expression of
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the REL and RELA NFKB subunits in LCC9 cells and the TNFa-induced expression
of NFKB1, REL, and RELB in LCC9.

As the NFKB subunits are also downstream

targets of the NFKB pathway themselves [306-309], this provides further evidence of
the decreased NFKB activation with COUP-TFII transfection.

The correlation

between COUP-TFII and NFKB target gene and subunit expression was further
examined through analysis of data from a microarray of gene expression in breast
tumors from ERa+ breast cancer patients treated with tamoxifen. Consistent with the
data in Chapter IV, an inverse correlation was found between COUP-TFII and
ICAM1,IL6, TNFAIP3, NFKB2, REL, RELA, and RELB in the patient samples. This

suggests that the same trend seen in the breast cancer cells is also true for breast
cancer patients.
To further investigate the mechanism of COUP-TFII regulation of NFKB
activation, the impact of COUP-TFII on NFKB DNA-binding was analyzed through
EMSA. COUP-TFII suppressed DNA-binding in both an in vitro assay where in vitro
transcribed/translated COUP-TFII was incubated with nuclear extract from LCC9
cells treated with TNFa, as well as in an EMSA with nuclear extract from MCF-7
and LCC9 cells transfected with COUP-TFII.

Further, co-immunoprecipitation

revealed that COUP-TFII interacts with NFKB subunits RelB and NFKB 1.

This

suggests COUP-TFII interaction with NFKB subunits inhibits binding to the NFKB
RE and decreases NFKB activation. COUP-TFII also inhibited induction of NFKB
activity by coactivators SRC-1, SRC-3, and CBP, implying that COUP-TFII and
NFKB compete for these coactivators, a mechanism that has been recently reported
for COUP-TFII action on other transcription factors [295] .
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Identification of COUP- TFII as a negative regulator of NFKB activity in
breast cancer cells provides valuable information about the possible mechanism by
which COUP- TFII helps prevent the progression to endocrine-resistance. It may
partly explain the ability of COUP-TFII to increase endocrine sensitivity [116], as
well as why endocrine-resistant cells (which have lower COUP- TFII expression) have
induced NFKB activity. These data also point to future use for COUP- TFII as both a
biomarker as well as a target for the enhancement of endocrine sensitivity. LCC9
endocrine-resistant cells were found to be more sensitive to treatment with an NFKB
inhibitor, and showed markedly reduced cell proliferation as compared to MCF-7
cells. This may be due to their increased dependence on the NFKB pathway for cell
survival, and may provide a target for therapeutic intervention.
Chapters III and IV have highlighted the importance of interacting proteins on
COUP-TFII function. The focus of the experiments described in Chapter V is to
identify proteins which differentially interact with COUP-TFII upon treatment with
tamoxifen. Many proteins were identified which could provide a starting point for
future studies. DAVID analysis was used to identify common themes amongst the
interacting proteins, including RNA splicing, calmodulin-binding, and ATP-binding.
As calmodulin was also found in the interacting proteins with EtOH (vehicle control)
treatment, and verified through co-immunoprecipitation in Chapter V, this could be
an interesting pathway for further investigation.
Also in Chapter V, the interaction between COUP-TFII and HSP27 was
verified through co-immunoprecipitation. Despite reports that HSP27 increase cell
proliferation and plays an oncogenic role in cancer progression [335-337], reduced
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HSP27 expression was found with increasing endocrine-resistance. Reduced HSP27
expression was also present in JIMT -1 trastuzumab-resistant breast cancer cells.
Conflicting reports have identified HSP27 as both increasing [322,342] and
decreasing drug resistance [321,324], and the interaction and positive correlation of
COUP-TFII and HSP27 merits further study. Phosphorylation of HSP27 at Serine 15,
78, and 82 also plays a role in cellular localization and function [319,325], and has
not been widely studied in resistance to antiestrogens or other drugs. A correlation of
HSP27 phosphorylation at Ser82 and drug resistance was not found in the endocrineresistant and trastuzumab-resistant cell lines studied in Chapter V, but further studies
will investigate phosphorylation at other serines. Subcellular localization of HSP27
in these cell lines will also be examined.
Overall, this study has provided important new information about the many
roles of COUP-TFII in breast cancer and confirmed the importance of COUP-TFII,
interacting proteins to its cellular function. Further investigation of the mechanisms
responsible for the ability of COUP-TFII to enhance endocrine sensitivity is crucial
for its use as a biomarker or therapeutic target. Identification of biomarkers to enable
detection of patients who would respond favorably to endocrine therapy would be of
great use, as would discovery of a target to reduce endocrine resistance in patients.
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APPENDIX I - SUPPLEMENTARY MATERIAL

Methods SI
Transient transfection with pCOUP-TFII-FLAG. MCF-7 cells, purchased from
ATCC, and used at passages <10, were transiently transfected with 2 I-1g pCOUPTFII-FLAG using the P-20 program of the Amaxa Nucleofection System. Cells were
'serum-starved' in phenol red-free IMEM supplemented with 5% dextran coated
charcoal stripped FBS (DCC-FBS) for 24 h before treatment with vehicle control
ethanol (EtOH) for 2 h as indicated in the experimental design (Fig. 1).

Protein identification by multidimensional protein identification technology
(MudPIT). Proteins eluted from the FLAG-affinity gel (Fig. 1) were digested by
trypsin, desalted with C18 spin columns, dried by speedvac, and fractionated by
strong cation exchange (SCX). The desalted samples were dissolved with loading
buffer containing 20% acetonitrile (ACN), 100 mM acetic acid (HAc), and 2 mM
~Acetate

Bioresources.
HAc~Ac

and then loaded on a pre-cleaned SCX cartridge from Michrom
After washing twice, peptides were eluted stepwise with 20 /-ll of
buffers with increasing ionic strength and pH (15 buffers and up to 10

mM HAcl615 mM NH4 Ac, pH 6.5). The SCX fractions were concentrated by

speedvac and diluted to 7 /-ll with 5% ACN/O.1% formic acid. 5 /-ll of the samples
were loaded to CapLC capillary LC system from Waters and peptides in the samples
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were separated with a 3.5

~m

Symmetry C18 column (75

~m

x 150 mm, Waters).

MS/MS spectra of the peptides were acquired by Q-TOF mass spectrometer (Waters) in
data dependent mode.

Proteins were identified by comparing MS/MS spectra with

sequences in Swiss-Prot database by ProteinLynx from Waters.

Immunofluorescence staining of pCOUP-TFII-FLAG.

Cells were grown on

coverslips, washed with PBS, fixed with cold methanol/acetone 1:1 for 5 min, and
washed twice with cold PBS. After blocking with 1% goat serum and 0.3 % Triton X100 in PBS for 30 min, primary FLAG antibody (Sigma) was added (1: 300 dilution) for
1 h. After removing the primary antibody, the cells were stained with secondary antimouse antibody labeled with Zenon™ Alexa Fluor 488 (Molecular Probes). Cells were
then incubated with ProLong@ Gold antifade reagent with DAPI (Molecular Probes).
Images (Fig. SI ) were captured using a Zeiss Axiovert200 inverted microscope with a
63x objective lens using AxioVision Release 4.3 software.
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Figure SI: Nuclear localization ofCOUP-TFII in transfected MCF-7 cells.
A, MCF-7 cells were either non-transfected (control) or transfected with pCOUP-TFIIFLAG for 48 h. Immunofluorescence staining was performed for FLAG as described in
Supplementary Materials and Methods. Cells were counterstained with DAPI (blue) to
image nuclei. The bar is 20 Jlm. Overlap images indicate localization ofCOUP-TFIIFLAG in the nucleus. B, Western blots of CE (30 Jlg) or NE (10 Jlg) from untransfected
MCF-7 cells (control) or transfected with pIRES-GFP-la parental vector or pCOUPTFII-FLAG with FLAG or ERa (AER320, ThermoFisher) antibodies. The two bands are
likely due to protein degradation. C, Ponceau S staining shows protein levels.
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Figure 82: Overexpression of COUP-TFII-FLAG in MCF-7 cells and
immunocapture ofCOUP-TF-FLAG by the anti-FLAG agarose affinity resin.
A, Briefly, MCF-7 cells were transiently transfected with C-terminal FLAG-tagged
COUP-TFII or empty vector for 24 h as described in Materials and Methods. WCEs were
prepared and incubated with EZ view Red ANTI-FLAG M2 Affinity gel (Sigma) for 16
h. After rinsing, proteins were eluted with serial glycine elutions: 1. 15 min at room
temperature for proteins associating with immobilized COUP-TFII-FLAG with moderate
affinity and 2. 5 min at 95°C to elute proteins bound to the immobilized COUP-TFIIFLAG with high affinity. Imrnunoprecipitating proteins were analyzed by MudPIT. Nonspecific proteins were subtracted from the total interacting proteins to identify proteins
specifically interacting with COUP-TFII-FLAG. B, 30 Jlg of WCE from LCC9, MCF-7
and MCF-7 cells transiently transfected with pCOUP-TFII-FLAG were separated by
SDS-PAGE and western blots were performed for COUP-TFII, FLAG and b-actin.
Quantitation of the COUP- TFII/~-actin in lanes 2 and 3 indicate a 2-fold increase COUPTFII in the transfected cells. TAM-R LCC9 cells served as a negative control, as we
reported lower COUP-TFII in LCC9 cells compared to parental MCF-7 cells (Riggs et al
Cancer Res. 66: 10188-98, 2006). Note FLAG signal was only detected in the
transfected cells (lane 2), indicating specificity. C, 1 mg of protein in WCE from COUPTFII-FLAG over-expressing MCF-7 cells was immunocaptured on anti-FLAG agarose
affinity beads. COUP-TFII and interacting proteins were eluted with 6 M urea. 30Jlg of
WCE were separated by SDS-PAGE in parallel to 30 Jlg unbound IP supernatant and
30Jlg eluted protein. COUP-TFII-FLAG-affinity bead binding is confirmed by decreased
FLAG in the Supernatant (flow-thru = 1mbound proteins) and enriched FLAG in the
eluted samples.
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Figure S3: Testing elution methods for retrieval of COUP-TFII-FLAG.
- 1 mg ofWCE from MCF-7 cells transfected with pCOUP-TFII-FLAG was
immunocaptured on the anti-FLAG affinity resin and eluted with sequential glycine
incubations: 1) 10 or 15 min room temperature (lanes 2 and 4) or 5 min. at 95°C (lanes 3
and 5) in two different experiments (Exp A or B), as indicated (lanes 2-5). Samples of
the indicated eluates were separated by SDS-PAGE and immunoblotted using anti-FLAG
antibody. 20 ~g of the IP supernatant, containing unbound COUP-TFII-FLAG, was run
in parallel as a control (lane 1). As seen in lane 5, incubation with glycine for 15 min.
followed by a 5 min. incubation of fresh glycine at 95°C (Exp. B) eluted the most intact
COUP-TFII-FLAG (-50 kDa). The increased temperature and incubation time of glycine
in Exp. B resulted in a FLAG-tagged degradation product(s) of -20 kDa (lanes 3-5).
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Figure 84: Endogenous nuclear nucleolin-COUP-TFII interaction in MCF-7 cells.
A, Equal amounts (100 f.lg) of protein of CE and NE from MCF-7 cells were
imrnunoprecipitated with nucleolin mAB (lanes 3 and 4), mouse (m) IgG (negative
control for mAB , lanes 5 and 6), COUP-TFII antisera (lanes 7 and 8), or rabbit (r) IgG
(negative control for IPs using COUP-TFII polyclonal antiserum, lanes 9 and 10),
followed by western blot for nucleolin and COUP-TFII. 20% (20 f.lg) input NE and CE
serve as loading controls (lanes 1 and 2). B, The relative amolmt of nucleolin and
COUP-TFII in the nucleolin IP was plotted relative to expression of each protein in the
input (set to 100). COUP-TFII in rabbit IgG IPs was not graphed because of the
contamination of the heavy IgG chain (lanes 7 and 8, COUP-TFII blot). Western blots
demonstrate that: 1) nucleolin interacts with COUP-TFII in the NE of MCF-7 cells (lane
7); 2) nucleolin is not IP' ed with rabbit IgG (lanes 9 and 10); 3) more COUP-TFII
interacts with nucleolin in NE IP' ed with nucleolin antibody than with mouse IgG (lane 3
versus lane 5). C, MCF-7 cells were treated with EtOH, 10 nM E2, or 100 nM 4-0HT for
1 h prior to separation of NE and CE. 200 f.lg of NE or CE were IP' ed with polyclonal
COUP-TFII antibody and imrnunoblotted with a monoclonal antibody (mAE) against
nucleolin. The blot was stripped and re-probed with mAE against COUP-TFII. D, 10%
input for NE and CE used in IP in part C.
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Figure S5: ChIP of COUP-TFII-FLAG on the RARB2 promoter in MCF-7 cells. A,
Chromatin immunoprecipitation was performed in MCF-7 cells transfected with pIRESCOUP-TFII-FLAG or empty vector, serum starved for 48 h, and treated with 1 ~ atRA
for 1 h. Following Q-PCR using primers to the RARB2 promoter as described in
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Figure 87: Effect of cell treatments on NR2F2 (COUP-TFII) expression in MCF-7
cells. A, Schematic diagram of transfection and treatment of MCF-7 cells. MCF-7 cells
were transfected with equal amounts of pT AG2 control vector or pCMV -nucleolin for 24
h., treated with 10 ~ CRO or ASI411, as indicted for 24 h, and 1 j.lM atRA was added
for the last 6 h. RNA was harvested and Q-PCR performed. B, NR2F2 values were
normalized to GAPDH. Values are the average of 6 separate experiments ± SEM. *
signific. different, p < 0.05 in one way ANOV A followed by Bonferroni multiple
comparison test. Note that there was no statistical difference between the pTAG+AS 1411
versus Nucl+AS I411 or ASI411 sample measurements of NR2F2.
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mining in Oncomine microarray data sets for NR2F2 in breast cancer identified that: A,
NR2F2 expression is significantly higher in ERa+ breast tumors (p < 0.007). B. NR2F2
is significantly lower in metastatic breast tumors (p < 0.05). Data are from (van de Vijver
MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med 2002; 347: 1999-2009).
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Table SI: Identification of proteins in MCF-7 WCE that non-specifically (NS)
interact with the anti-FLAG-affinity resin.
1 mg protein in WCE from EMPTY-FLAG vector-transfected MCF-7 cells was
incubated with anti-FLAG affinity gel, eluted with 0.1 M glycine, pH 3.5 for 15 min. at
RT, and subjected to MudPIT peptide identification. Matched number (No) indicates the
number of sequenced peptides that match the full length protein. Coverage indicates the
% of the total protein matched.

Protein name

Accession
~Gll

Mass
~Mrl

pi

Cytoskeletal proteins
Actin cytoplasm ic 1
Tropomyosin alpha-4 chain
Tropomyosin alpha-3 chain
Myosin-9
Tropomyosin beta chain
Tropomyosin alpha-1 chain
Myosin light polypeptide 6

P60709
P67936
P06753
P35579
P07951
P09493
P60660

41710
28505
29015
226392
32970
32689
16788

Histones
Histone H4

P62805

11 229

167

Matched

~N°l

Coverage
~%l

5.4
4.7
4.8
4.6
4.7
4.7
4.6

4
4
4
4
5
4
3

15.5
17.3
18.1
3.0
23.6
14.8
22.7

11.4

3

29.4

Table 82: Identification of proteins 'moderately' associated with COUP-TFII in
MCF-7 cells.
1 mg protein in WCE from pCOVP-TFII-FLAG transfected, EtOH-treated MCF-7 cells
was incubated with anti-FLAG affinity gel, eluted with 0.1 M glycine, pH 3.5 for 15 h at
RT, and subjected to MudPIT peptide identification. Matched number (No) indicates the
number of sequenced peptides that match the full length protein. Coverage indicates the
% of the total protein matched. This table excludes proteins that were nonspecifically
associated with the anti-FLAG affinity gel as summarized in Table Sl.

Protein name (gene)
Ribonucleoproteins
Heterogeneous nuclear
ribonucleoprotein DO
Histones
Histone H2A.Z
Core histone macro-H2A.1
Histone H1.5
Histone H1 .2
Histone H3.1
Other Proteins
Heat Shock 70 kOa protein B
(HSPA7)
Heat Shock 70 kOa protein 1
HSP70 (HSPA1A)
Chromobox Protein Homolog 3
(CBX3)

Accession
~GIl

Mass

Q14103

22435

POCOS5
075367
P16401
P16403
P68431

~Nol

Coverage
~%l

11.3

2

10.2

13414
39445
22435
21221
15263

10.9
10.1
11.3
11.3
11.3

2
2
3
3
2

7.9-16
5.4
10.2
10.8
10.4

P48741

26890

7.6

3

16.2

P08107

70009

5.6

3

6.2

Q13185

19708

5.1

3

6.4
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Figure S10. Expression of COUP-TFII in transfected MCF -7 and LCC9 cells.
MCF-7 and LCC9 cells were transfected with pcDNA3.1 or pcDNA3.1-COUP-TFII for
48 h and treated with 10 ng/ml TNFa for 6 h before preparing whole cell extracts.
Expression of COUP- TFII was analyzed by western blot and compared to ~-actin control.
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Figure Sl1. Specificity of protein complex binding to NFKB-RE DNA probe.
Full EMSA picture from Fig. 6B. 25 j.lg NE prepared from MCF-7 and LCC9 cells
transfected with pcDNA3 .1 or pcDNA3.1-COUP-TFII for 48 h and treated with TNFa
for 6 h was incubated with 2PJNFKB-RE DNA probe +/- lOOX cold unlabeled DNA
probe for 1 h to perform EMSA. Binding to 2PJNFKB-RE DNA probe is inhibited by
the addition of excess cold DNA probe.
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Figure S12. BMS-345541 inhibits NFKB activity in MCF-7 and LCC9 cells.
MCF-7 and LCC9 cells were semm-starved for 24 h before being transfected with a
NFKB luciferase reporter for 48 h and treated with various concentrations of an NFKB
inhibitor, BMS-345541 +/- 10 ng/ml TNFa for 6 h. Dualluciferase assay was performed
to verify that the BMS-345541 inhibited NFKB activity at these concentrations. Firefly
luciferase values are shown relative to pGL4-hRluc-TK Renilla (Promega). Note higher
NFKB activity in semm-starved MCF-7 cells as compared to normal media (Figure 1).
*: P<O.05 versus DMSO control for each cell line.
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GPA 3.948

RESEARCH EXPERIENCE
2007-08

Undergraduate Research
The role of nucleolin in the mechanism of novel anticancer agent,
AS1411
University of Louisville School of Medicine
Mentor: Dr. Paula J. Bates

2008-13

Doctoral Research
COUP-TFII and its interacting proteins in breast cancer and
endocrine resistance
Department of Biochemistry and Molecular Biology
University of Louisville School of Medicine
Mentor: Dr. Carolyn M. Klinge

HONORS
2005-Present

Golden Key International Honour Society

172

2008
2008
2008-10
2010-12
2012

2013
2013

University honors scholar, University of Louisville, Louisville, KY
Summa cum laude graduate, University of Louisville, Louisville,
KY
Integrated Programs in Biomedical Sciences Fellowship
NIEHS T32-ES011564 Predoctoral Fellowship
First place award in poster competition at Research!Louisville,
University of Louisville School of Medicine, Louisville, KY,
September 18,2012. Litchfield, L.M. and Klinge, C.M. COUPTFII suppresses NFKB activation in endocrine-resistant breast
cancer cells. (Abstract #56)
John M. Houchens Award for most meritorious dissertation
Graduate Dean's Citation

PUBLICATIONS
1. Litchfield, L.M., Riggs, K.A., Hockenberry, A.M., Oliver, L.D., Barnhart, K.G.,
Cai, J., Pierce, W.M., Ivanova, M.M., Bates, PJ., Appana, S.N., Datta, S.,
Kulesza, P., McBryan, J., Young, L.S., Klinge, C.M. Identification and
Characterization of Nucleolin as a COUP-TFII Coactivator of Retinoic Acid
Receptor ~ Transcription in Breast Cancer Cells. PLoS ONE 7(5): e38278, 2012.
doi: 10. 1371/journal.pone.0038278
2. Litchfield, L.M. and Klinge, C.M. Multiple roles of COUP-TFII in cancer
initiation and progression. Journal of Molecular Endocrinology, 49(3): R135-48,
2012. doi:1D.1530/JME-12-0144
3. Manavalan, T.T.*, Teng, Y*, Litchfield, L.M.*, Muluhngwi, P., AI-Rayyan, N.,
Klinge, C.M. Reduced expression of miR-200 family members contributes to
antiestrogen resistance in LY2 human breast cancer cells. PLoS ONE, In
publication. *equal contribution
4. Litchfield, L.M. and Klinge, C.M. COUP-TFII inhibits NFKB activation in
breast cancer cells and restores endocrine sensitivity. In submission.

PROFESSIONAL MEMBERSmpS
20 II-Present
2012-Present
2012-Present
20 12-Present

The Endocrine Society
American Association for Cancer Research
Women in Cancer Research
Kentucky Academy of Science
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ORAL PRESENTATIONS
1. Litchfield, L.M., Emberts, e.G., and Klinge, e.M. COUP-TFII-Nucleolin
Interaction Regulates RAR~2 Expression in Human Breast Cancer Cells. Oral
Presentation at the 2011 Colloquium of Biochemistry and Molecular Biology,
University of Louisville School of Medicine, August 26, 2011.

POSTER PRESENTATIONS
Abstracts of poster presentations (national):
1. Litchfield, L.M., Emberts, C.G., and Klinge, e.M. COUP-TFII-Nucleolin
Interaction Regulates RAR[beta]2 Expression in Human Breast Cancer Cells
(Abstract P2-1O) Abstracts of the 93rd annual meeting of the Endocrine Society,
Boston, MA, June 5, 2011.
2. Litchfield, L.M., Cai, J., Pierce, W .M., Appana, S.N., Bates, PJ., Datta, S.,
Kulesza, P., Young, L.S., and Klinge, e.M. Identification and fimctional
characterization of COUP-TFII-nucleolin interaction in breast cancer cells and
tumors. AACR Advances in Breast Cancer Research: Genetics, Biology, and
Clinical Applications meeting, San Francisco, CA, October 14, 2011 .
3. Litchfield, L.M. and Klinge, C.M. COUP-TFII suppresses NFK13 activation in
endocrine-resistant breast cancer cells. (Abstract #2214) The 103rd annual
meeting of the American Association for Cancer Research, Chicago, IL, April 2,
2012.
4. Litchfield, L.M. and Klinge, C.M. COUP-TFII suppresses NFK13 activation in
endocrine-resistant breast cancer cells. (P6-04-30) CTRC-AACR San Antionio
Breast Cancer Symposium, San Antonio, TX, December 8, 2012.

Abstracts of poster presentations (local):
1. Fox, J.M., Litchfield, L.M., Emberts, C.G., Clark, B.J., and Klinge, C.M.

2.

3.

4.

5.

Characterization of the impact of nucleolin on COUP-TFII-mediated regulation
of ERa, ER~, RAR~ and StAR transcription in MCF-7 Human Breast Cancer
Cells. (Abstract MED-19) Research!Louisville, University of Louisville School of
Medicine, Louisville, KY, October 14, 2009.
Oliver, L.D., Litchfield, L.M., and Klinge, e.M. The effect of COUP-TFIInucleolin interaction on RAR~2 expression in human breast cancer cells. SROP
poster presentation. University of Louisville School of Medicine, Louisville, KY,
August 1,2010.
Litchfield, L.M., Emberts, e.G., and Klinge, C.M. The effect of COUP-TFIInucleolin interaction on RAR~2 expression in human breast cancer cells.
(Abstract GRD-40) Research!Louisville, University of Louisville School of
Medicine, Louisville, KY, October 13,2010.
Oliver, L.D., Litchfield, L.M., and Klinge, e.M. The effect of COUP-TFIInucleolin interaction on RAR~2 expression in human breast cancer cells. Posters
at the Capitol. Frankfort, KY, February 10,2011.
Litchfield, L.M., Emberts, C.G., and Klinge, e.M. The effect of COUP-TFII-
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nucleolin interaction on RAR~2 expression in human breast cancer cells. 13 th
annual Institute for Molecular Diversity and Drug Design (IMD3) Symposium,
March 8, 2011.
6. Barnhart, K.G., Litchfield, L.M., and Klinge, C.M. Effect ofCOUP-TFII on
RAR~2 and NFKB Expression in Breast Cancer Cells. SROP poster presentation.
University of Louisville School of Medicine, Louisville, KY, August 1, 2011.
7. Litchfield, L.M., Emberts, C.G., and Klinge, C.M. COUP-TFII-Nucleolin
Interaction Regulates RAR~2 Expression in Human Breast Cancer Cells.
(Abstract GRD-52) Research!Louisville, University of Louisville School of
Medicine, Louisville, KY, October 11,2011.
8. Litchfield, L.M., Emberts, e.G., and Klinge, C.M. COUP-TFII-Nucleolin
Interaction Regulates RAR~2 Expression in Human Breast Cancer Cells.
(Abstract #76) 10th annual Brown Cancer Center Retreat, Louisville, KY, October
28, 2011.
9. Litchfield, L.M. and Klinge, e.M. COUP-TFII suppresses NFKB activation in
endocrine-resistant breast cancer cells. (Abstract #31) 14th annual Institute for
Molecular Diversity and Drug Design (IMD3) Symposium, March 13,2012.
10. Litchfield, L.M. and Klinge, e.M. COUP-TFII suppresses NFKB activation in
endocrine-resistant breast cancer cells. (Abstract #56) Research!Louisville,
University of Louisville School of Medicine, Louisville, KY, September 18,
2012.
11 . Litchfield, L.M. and Klinge, C.M. COUP-TFII suppresses NFKB activation in
endocrine-resistant breast cancer cells. 11th annual Brown Cancer Center Retreat,
Louisville, KY, October 26,2012.
12. Litchfield, L.M. and Klinge, C.M. COUP-TFII suppresses NFKB activation in
endocrine-resistant breast cancer cells. 15 th annual Institute for Molecular
Diversity and Drug Design (IMD3) Symposium, March 12, 2012.
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